

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08224 A1

(51) International Patent Classification: C07D 401/14,
A61K 31/47, 31/445, 31/4725, A61P 31/04, C07D 401/12
// (C07D 401/14, 215:00, 211:00, 209:00) (C07D 401/14,
307:00, 215:00, 211:00) (C07D 401/14, 333:00, 215:00,
211:00)

Third Avenue, Harlow, Essex CM19 5AW (GB). PEAR-
SON, Neil, David [GB/GB]; GlaxoSmithKline, New
Frontiers Science Park South, Third Avenue, Harlow,
Essex CM19 5AW (GB).

(21) International Application Number: PCT/EP01/08604

(74) Agent: VALENTINE, Jill; Corporate Intellectual Prop-
erty, GlaxoSmithKline, Two New Horizons Court, Brent-
ford, Middlesex TW8 9EP (GB).

(22) International Filing Date: 25 July 2001 (25.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0018351.7 26 July 2000 (26.07.2000) GB
0101629.4 22 January 2001 (22.01.2001) GB

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): DAVIES, David,
Thomas [GB/GB]; GlaxoSmithKline, New Frontiers
Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB). JONES, Graham, Elgin [GB/GB]; Glaxo-
SmithKline, New Frontiers Science Park South, Third
Avenue, Harlow, Essex CM19 5AW (GB). LIGHTFOOT,
Andrew, P. [GB/GB]; GlaxoSmithKline, New Frontiers
Science Park South, Third Avenue, Harlow, Essex CM19
5AW (GB). MARKWELL, Roger, Edward [GB/GB];
GlaxoSmithKline, New Frontiers Science Park South,

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL AC-
TIVITY



(I)

(57) Abstract: Aminopiperidine deriva-
tives of formula (I) and pharmaceutically
acceptable derivatives thereof useful
in methods of treatment of bacterial
infections in mammals, particularly in
man.

WO 02/08224 A1

P 42
ex 20

AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY


This invention relates to novel compounds, compositions containing them and their use as antibacterials.

5 WO99/37635, WO00/21948, WO00/21952, WO00/25227, WO00/43383, WO00/78748, WO01/07432 and WO01/07433 disclose piperidine and piperazine derivatives having antibacterial activity.

WO9717957 discloses piperidyl compounds which are haemoregulatory and stimulate haematopoiesis. JP07179407 discloses piperidyl compounds which are useful for
10 preventing thrombotic diseases, inhibiting tumour metastasis and accelerating wound healing.

We have now found a novel group of aminopiperidines which have antibacterial activity.

This invention provides a compound of formula (I) or a pharmaceutically
15 acceptable derivative thereof:



(I)

wherein:

20

one of Z¹, Z², Z³, Z⁴ and Z⁵ is N, one is CR^{1a} and the remainder are CH, or one or two of Z¹, Z², Z³, Z⁴ and Z⁵ are independently CR^{1a} and the remainder are CH;


R¹ and R^{1a} are independently hydrogen; hydroxy; (C₁₋₆)alkoxy optionally substituted by
25 (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, CONH₂, hydroxy, (C₁₋₆)alkylthio, heterocyclythio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted(C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; trifluoromethyl; trifluoromethoxy; nitro; azido; acyl; acyloxy;
30 acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups;

provided that when Z¹, Z², Z³, Z⁴ and Z⁵ are CR^{1a} or CH, then R¹ is not hydrogen;

R² is hydrogen, or (C₁₋₄)alkyl or (C₂₋₄)alkenyl optionally substituted with 1 to 3 groups selected from:

- 5 amino optionally substituted by one or two (C₁₋₄)alkyl groups; carboxy; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₄)alkyl, hydroxy(C₁₋₄)alkyl, aminocarbonyl(C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₁₋₄)alkylsulphonyl, trifluoromethylsulphonyl, (C₂₋₄)alkenylsulphonyl, (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl or (C₂₋₄)alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R¹⁰; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R¹⁰; 5-oxo-1,2,4-oxadiazol-3-yl; halogen; (C₁₋₄)alkylthio; trifluoromethyl; hydroxy optionally substituted by (C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl; oxo; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or (C₁₋₄)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl;
- 15
- 20 R³ is hydrogen; or
R³ is in the 2-, 3- or 4-position and is:
carboxy; (C₁₋₆)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₂₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R¹⁰; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R¹⁰; or 5-oxo-1,2,4-oxadiazol-3-yl; or
30 (C₁₋₄)alkyl or ethenyl optionally substituted with any of the substituents listed above for R³ and/or 0 to 2 groups R¹² independently selected from:
halogen; (C₁₋₆)alkylthio; trifluoromethyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋
- 35

- 6)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl
- 5 wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino
- 10 group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; or when R³ is in the 3-position, hydroxy optionally substituted as described above; in addition when R³ is disubstituted with a hydroxy or amino containing substituent and carboxy containing substituent these may together form a cyclic ester or amide linkage, respectively;
- 15 R⁴ is a group -U-R⁵ where
U is selected from CO, SO₂ and CH₂ and
R⁵ is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



- containing up to four heteroatoms in each ring in which
- 20 ring (a) is aromatic or non aromatic;
X¹ is C when part of an aromatic ring or CR¹⁴ when part of a non aromatic ring;
X² is N, NR¹³, O, S(O)_x, CO or CR¹⁴ when part of an aromatic or non-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of a non aromatic ring;
X⁴ is N, NR¹³, O, S(O)_x, CO or CR¹⁴;
- 25 X³ and X⁵ are independently N or C;
Y¹ is a 1 to 3 atom linker group each atom of which is independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring,
Y² is a 2 or 3 atom linker group completing an aromatic ring, each atom of Y²
- 30 being independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴;
each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy;
- 35 hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or

aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; aryl(C₁₋₄)alkoxy or

5 R¹⁴ and R¹⁵ may together represent oxo;

each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, carboxy, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl (C₁₋₄)alkyl; arylcarbonyl; heteroarylcarbonyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenylloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl;

n is 0 or 1;

15

each x is independently 0, 1 or 2

A is NR¹¹, O or CR⁶R⁷ and B is NR¹¹, O, SO₂ or CR⁸R⁹ and wherein:

each of R⁶, R⁷, R⁸ and R⁹ is independently selected from: hydrogen; (C₁₋₆)alkoxy; (C₁₋₆)alkylthio; halo; trifluoromethyl; azido; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenylloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl;

25

or when n=1 R⁶ and R⁸ together represent a bond and R⁷ and R⁹ are as above defined; or R⁶ and R⁷ or R⁸ and R⁹ together represent oxo;

provided that:

30

when A is NR¹¹, B is not NR¹¹ or O;

when A is CO, B is not CO, O or SO₂;

when n is 0 and A is NR¹¹, CR⁸R⁹ can only be CO;

when A is CR⁶R⁷ and B is SO₂, n is 0;

when n is 0, B is not NR¹¹ or O or R⁸ and R⁹ are not optionally substituted hydroxy or amino;

35

when A is O, B is not NR¹¹, O, SO₂ or CO and n=1; and

when A-B is CR⁷=CR⁹, n is 1

R¹⁰ is selected from (C₁₋₄)alkyl; (C₂₋₄)alkenyl and aryl any of which may be optionally substituted by a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₂₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; (C₁₋₆)alkylsulphonyl; trifluoromethylsulphonyl; (C₂₋₆)alkenylsulphonyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; and (C₂₋₆)alkenylcarbonyl; and

R¹¹ is hydrogen; trifluoromethyl, (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₂₋₆)alkenyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl;

or where one of R³ and R⁶, R⁷, R⁸ or R⁹ contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage.

This invention also provides a method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.

The invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.

The invention also provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.

In one aspect, when U is CH₂, R⁵ is not a heteroaryl group. In another aspect, when U is CH₂, R⁵ is not indolyl, quinolinyl or benzothienyl.

Preferably one of Z¹, Z², Z³, Z⁴ and Z⁵ is N, one is CR^{1a} and the remainder are CH, or one of Z¹, Z², Z³, Z⁴ and Z⁵ is CR^{1a} and the remainder are CH.

Preferably Z⁵ is CH or N, Z³ is CH or CF and Z¹, Z² and Z⁴ are each CH, or Z¹ is N, Z³ is CH or CF and Z², Z⁴ and Z⁵ are each CH.

When R^1 or R^{1a} is substituted alkoxy it is preferably (C₂₋₆)alkoxy substituted by optionally N-substituted amino, guanidino or amidino, or (C₁₋₆)alkoxy substituted by piperidyl. Suitable examples of R^1 and R^{1a} alkoxy include methoxy, trifluoromethoxy, n-propyloxy, iso-butyloxy, aminoethyloxy, aminopropyloxy, aminobutyloxy,
 5 aminopentyloxy, guanidinopropyloxy, piperidin-4-ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy.

Preferably R^1 and R^{1a} are independently methoxy, amino(C₃₋₅)alkyloxy, guanidino(C₃₋₅)alkyloxy, piperidyl(C₃₋₅)alkyloxy, nitro or fluoro; R^1 is more preferably methoxy, amino(C₃₋₅)alkyloxy or guanidino(C₃₋₅)alkyloxy. R^{1a} is more preferably H or
 10 F. Most preferably R^1 is methoxy. and R^{1a} is H or when Z^3 is CR^{1a} it may be C-F.

When Z^5 is CR^{1a}, R^{1a} is preferably hydrogen, cyano, hydroxymethyl or carboxy, most preferably hydrogen.

Preferably n is 0.

R^2 is preferably hydrogen; (C₁₋₄)alkyl substituted with carboxy, optionally
 15 substituted hydroxy, optionally substituted aminocarbonyl, optionally substituted amino or (C₁₋₄)alkoxycarbonyl; or (C₂₋₄)alkenyl substituted with (C₁₋₄)alkoxycarbonyl or carboxy. More preferred groups for R^2 are hydrogen, carboxymethyl, hydroxyethyl, aminocarbonylmethyl, ethoxycarbonylmethyl, ethoxycarbonylallyl and carboxyallyl, most preferably hydrogen.

Preferred examples of R^3 include hydrogen; optionally substituted hydroxy; (C₁₋₄) alkyl; ethenyl; optionally substituted 1-hydroxy-(C₁₋₄) alkyl; optionally substituted aminocarbonyl; carboxy(C₁₋₄)alkyl; optionally substituted aminocarbonyl(C₁₋₄)alkyl; cyano(C₁₋₄)alkyl; optionally substituted 2-oxo-oxazolidinyl and optionally substituted 2-oxo-oxazolidinyl(C₁₋₄alkyl). More preferred R^3 groups are hydrogen; CONH₂; 1-
 20 hydroxyalkyl e.g. CH₂OH, CH(OH)CH₂CN; CH₂CO₂H; CH₂CONH₂; -CONHCH₂CONH₂; 1,2-dihydroxyalkyl e.g. CH(OH)CH₂OH; CH₂CN; 2-oxo-oxazolidin-5-yl and 2-oxo-oxazolidin-5-yl(C₁₋₄alkyl). Most preferably R^3 is hydrogen.

R^3 is preferably in the 3- or 4-position.

When R^3 and R^6 , R^7 , R^8 or R^9 together form a cyclic ester or amide linkage, it is
 30 preferred that the resulting ring is 5-7 membered. It is further preferred that the group A or B which does not form the ester or amide linkage is CH₂.

When A is CH(OH) the R-stereochemistry is preferred.

Preferably A is NH, NCH₃, CH₂, CHOH, CH(NH₂), C(Me)(OH) or CH(Me).

Preferably B is CH₂ or CO.

35 Preferably A-B is CHOH-CH₂, NR¹¹-CH₂ or NR¹¹-CO.

Particularly preferred are those compounds where n=0, A is NH and B is CO, or A is CHOH and B is CH₂, when more preferably A is the R-isomer of CHOH.

Preferably R¹¹ is hydrogen or (C₁₋₄)alkyl e.g. methyl, more preferably hydrogen.
U is most preferably CH₂.

Preferably R⁵ is an aromatic heterocyclic ring (A) having 1-4 heteroatoms of which one is N or NR¹³.

5 Examples of rings (A) include optionally substituted:

(a) and (b) aromatic

1H-pyrrolo[2,3-b]-pyridin-2-yl, 1H-pyrrolo[3,2-b]-pyridin-2-yl, 3H-imidazo[4,5-b]-pyridin-2-yl, 3H-quinazolin-4-one-2-yl, benzimidazol-2-yl, benzo[1,2,3]-thiadiazol-5-yl, benzo[1,2,5]-oxadiazol-5-yl, benzofur-2-yl, benzothiazol-2-yl, benzo[b]thiophen-2-yl, benzoxazol-2-yl, chromen-4-one-3-yl, imidazo[1,2-a]pyridin-2-yl, imidazo-[1,2-a]-pyrimidin-2-yl, indol-2-yl, indol-6-yl, isoquinolin-3-yl, [1,8]-naphthyridine-3-yl, oxazolo[4,5-b]-pyridin-2-yl, quinolin-2-yl, quinolin-3-yl, quinoxalin-2-yl, indan-2-yl, naphthalen-2-yl, 1,3-dioxo-isoindol-2-yl, benzimidazol-2-yl, benzothiophen-2-yl, 1H-benzotriazol-5-yl, 1H-indol-5-yl, 3H-benzoxazol-2-one-6-yl, 3H-benzoxazol-2-thione-6-yl, 3H-benzothiazol-2-one-5-yl, 3H-quinazolin-4-one-2-yl, 3H-quinazolin-4-one-6-yl, 4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl, benzo[1,2,3]thiadiazol-6-yl, benzo[1,2,5]thiadiazol-5-yl, benzo[1,4]oxazin-2-one-3-yl, benzothiazol-5-yl, benzothiazol-6-yl, cinnolin-3-yl, imidazo[1,2-a]pyridazin-2-yl, imidazo[1,2-b]pyridazin-2-yl, pyrazolo[1,5-a]pyrazin-2-yl, pyrazolo[1,5-a]pyridin-2-yl, pyrazolo[1,5-a]pyrimidin-6-yl, pyrazolo[5,1-c][1,2,4]triazin-3-yl, pyrido[1,2-a]pyrimidin-4-one-2-yl, pyrido[1,2-a]pyrimidin-4-one-3-yl, quinazolin-2-yl, quinoxalin-6-yl, thiazolo[3,2-a]pyrimidin-5-one-7-yl, thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-b]pyridin-6-yl, thieno[3,2-b]pyridin-6-yl, 2H-isoquinolin-1-one-3-yl.

25 (a) is non aromatic

(2S)-2,3-dihydro-1H-indol-2-yl, (2S)-2,3-dihydro-benzo[1,4]dioxine-2-yl, 3-(R,S)-3,4-dihydro-2H-benzo[1,4]thiazin-3-yl, 3-(R)-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl, 2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl, and 3-substituted-3H-quinazolin-4-one-2-yl.

30 In one aspect, when R¹³ is optionally substituted (C₁₋₄)alkyl, the optional substituent is other than carboxy.

R¹³ is preferably H if in ring (a) or in addition (C₁₋₄)alkyl such as methyl or isopropyl when in ring (b). More preferably, in ring (b) R¹³ is hydrogen when NR¹³ is bonded to X³ and (C₁₋₄)alkyl when NR¹³ is bonded to X⁵.

35 R¹⁴ and R¹⁵ are preferably independently selected from hydrogen, halo, hydroxy, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, trifluoromethoxy, nitro, cyano, aryl(C₁₋₄)alkoxy and (C₁₋₄)alkylsulphonyl. More preferably R¹⁵ is hydrogen.

More preferably each R¹⁴ is selected from hydrogen, chloro, fluoro, hydroxy, methyl, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl. Most preferably R¹⁴ is selected from hydrogen, hydroxy, fluorine or nitro. Preferably 0-3 groups R¹⁴ are substituents other than hydrogen. Preferably when R¹⁴ is not hydrogen,
 5 X⁴ is CR¹⁴ and/or CR¹⁴ is a component of Y².

Most preferred groups R⁵ include 4,6-difluoro-indol-2-yl, 1H-pyrrolo[2,3-b]-pyridin-2-yl, 1H-pyrrolo[3,2-b]-pyridin-2-yl, 8-hydroxy-quinolin-2-yl, quinoxalin-2-yl, benzimidazol-2-yl, benzo[1,2,3]-thiadiazol-5-yl, benzothiophen-2-yl, 4,6-difluoro-1H-benzimidazol-2-yl, benzothiazole-5-yl and 3-(R)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-
 10 3-yl.

When used herein, the term "alkyl" includes groups having straight and branched chains, for instance, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, pentyl and hexyl. The term 'alkenyl' should be interpreted accordingly.

Halo or halogen includes fluoro, chloro, bromo and iodo.

15 Haloalkyl moieties include 1-3 halogen atoms.

Unless otherwise defined, the term "heterocyclic" as used herein includes optionally substituted aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or C-substituted by, for example, up to three
 20 groups selected from (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano, carboxy, amino or aminocarbonyl
 25 optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; optionally substituted aryl, aryl(C₁₋₄)alkyl or aryl(C₁₋₄)alkoxy and oxo groups.

Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A
 30 fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring. Compounds within the invention containing a heterocyclyl group may occur in two or more tautomeric forms depending on the nature of the heterocyclyl group; all such tautomeric forms are included within the scope of the invention.

Where an amino group forms part of a single or fused non-aromatic heterocyclic
 35 ring as defined above suitable optional substituents in such substituted amino groups include H; trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; (C₁₋

4)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl, (C₁₋₄)alkyl or (C₂₋₄)alkenyl and optionally further substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl.

5 When used herein the term "aryl", includes optionally substituted phenyl and naphthyl.

Aryl groups may be optionally substituted with up to five, preferably up to three, groups selected from (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; phenyl, phenyl(C₁₋₄)alkyl or phenyl(C₁₋₄)alkoxy

15 The term "acyl" includes formyl and (C₁₋₆)alkylcarbonyl group.

Preferred compounds of formula (I) include:

- (R)-2-{4-[(4-fluoro-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol;
- 20 (R)-1-(6-methoxy-quinolin-4-yl)-2-{4-[(1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol;
- 2-(1-[(R)-2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-4-ylamino)-methyl-quinolin-8-ol;
- (R)-2-{4-[(benzo[1,2,3]thiadiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol;
- 25 (R)-1-(6-methoxy-quinolin-4-yl)-2-{4-[(quinoxalin-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol;
- 2-(1-[(R)-2-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-piperidin-4-ylamino)-methyl-quinolin-8-ol;
- 30 4-[(4,7-difluoro-1H-indol-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- (R)-2-(4-{[(R)-1-(2,3-Dihydro-[1,4]dioxino[2,3-]pyridin-3-yl)methyl]-amino}-piperidin-1-yl)-1-(8-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (R)-2-{4-[(Benzothiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol; and
- 35 (R)-2-{4-[(4,6-Difluoro-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy[1,5]naphthyridin-4-yl)-ethanol;
- and pharmaceutically acceptable derivatives thereof.


Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or pharmaceutically acceptable derivative thereof.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable derivatives.

Pharmaceutically acceptable derivatives of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids. Compounds of formula (I) may also be prepared as the N-oxide. Compounds of formula (I) having a free carboxy group may also be prepared as an *in vivo* hydrolysable ester. The invention extends to all such derivatives.

Examples of suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming groups include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v):




5

wherein R^a is hydrogen, (C₁₋₆) alkyl, (C₃₋₇) cycloalkyl, methyl, or phenyl, R^b is (C₁₋₆) alkyl, (C₁₋₆) alkoxy, phenyl, benzyl, (C₃₋₇) cycloalkyl, (C₃₋₇) cycloalkyloxy, (C₁₋₆) alkyl (C₃₋₇) cycloalkyl, 1-amino (C₁₋₆) alkyl, or 1-(C₁₋₆ alkyl)amino (C₁₋₆) alkyl; or R^a and R^b together form a 1,2-phenylene group optionally substituted by one or two methoxy groups; R^c represents (C₁₋₆) alkylene optionally substituted with a methyl or ethyl group and R^d and R^e independently represent (C₁₋₆) alkyl; R^f represents (C₁₋₆) alkyl; R^g represents hydrogen or phenyl optionally substituted by up to three groups selected from halogen, (C₁₋₆) alkyl, or (C₁₋₆) alkoxy; Q is oxygen or NH; R^h is hydrogen or (C₁₋₆) alkyl; R^i is hydrogen, (C₁₋₆) alkyl optionally substituted by halogen, (C₂₋₆) alkenyl, (C₁₋₆) alkoxycarbonyl, aryl or heteroaryl; or R^h and R^i together form (C₁₋₆) alkylene; R^j represents hydrogen, (C₁₋₆) alkyl or (C₁₋₆) alkoxycarbonyl; and R^k represents (C₁₋₈) alkyl, (C₁₋₈) alkoxy, (C₁₋₆) alkoxy(C₁₋₆)alkoxy or aryl.

Examples of suitable *in vivo* hydrolysable ester groups include, for example, acyloxy(C₁₋₆)alkyl groups such as acetoxymethyl, pivaloyloxymethyl, α -acetoxylethyl, α -pivaloyloxyethyl, 1-(cyclohexylcarbonyloxy)prop-1-yl, and (1-aminoethyl)carbonyloxymethyl; (C₁₋₆)alkoxycarbonyloxy(C₁₋₆)alkyl groups, such as ethoxycarbonyloxymethyl, α -ethoxycarbonyloxyethyl and propoxycarbonyloxyethyl; di(C₁₋₆)alkylamino(C₁₋₆)alkyl especially di(C₁₋₄)alkylamino(C₁₋₄)alkyl groups such as

dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethyl;
 2-((C₁₋₆)alkoxycarbonyl)-2-(C₂₋₆)alkenyl groups such as
 2-(isobutoxycarbonyl)pent-2-enyl and 2-(ethoxycarbonyl)but-2-enyl; lactone groups such
 as phthalidyl and dimethoxyphthalidyl.

- 5 A further suitable pharmaceutically acceptable *in vivo* hydrolysable ester-forming group is that of the formula:



wherein R^k is hydrogen, C₁₋₆ alkyl or phenyl.


- 10 R is preferably hydrogen.

Compounds of formula (I) may also be prepared as the corresponding N-oxides.


- Certain of the compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. For example the
 15 invention includes compound in which an A-B group CH(OH)-CH₂ is in either isomeric configuration, the *R*-isomer is preferred. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

- In a further aspect of the invention there is provided a process for preparing
 20 compounds of formula (I), and pharmaceutically acceptable derivatives thereof, which process comprises:

reacting a compound of formula (IV) with a compound of formula (V):



(IV)




(V)

wherein n is as defined in formula (I); Z^{1'}, Z^{2'}, Z^{3'}, Z^{4'}, Z^{5'}, R^{1'} and R^{3'} are Z¹, Z², Z³, Z⁴, Z⁵, R¹ and R³ as defined in formula (I) or groups convertible thereto;

Q^1 is $NR^{2'}R^{4'}$ or a group convertible thereto wherein $R^{2'}$ and $R^{4'}$ are R^2 and R^4 as defined in formula (I) or groups convertible thereto and Q^2 is H or $R^{3'}$ or Q^1 and Q^2 together form an optionally protected oxo group;
and X and Y may be the following combinations:

- 5 (i) X is A'-COW, Y is H and n is 0;
- (ii) X is $CR^6=CR^8R^9$, Y is H and n is 0;
- (iii) X is oxirane, Y is H and n is 0;
- (iv) X is $N=C=O$ and Y is H and n is 0;
- (v) one of X and Y is CO_2R^Y and the other is $CH_2CO_2R^X$;
- 10 (vi) X is CHR^6R^7 and Y is $C(=O)R^9$;
- (vii) X is $CR^7=PR^Z_3$ and Y is $C(=O)R^9$ and $n=1$;
- (viii) X is $C(=O)R^7$ and Y is $CR^9=PR^Z_3$ and $n=1$;
- (ix) Y is COW and X is $NHR^{11'}$, NCO or $NR^{11'}COW$ and $n=0$ or 1 or when $n=1$ X is COW and Y is $NHR^{11'}$, NCO or $NR^{11'}COW$;
- 15 (x) X is $C(O=)R^6$ and Y is $NHR^{11'}$ or X is $NHR^{11'}$ and Y is $C(=O)R^8$ and $n=1$;
- (xi) X is $NHR^{11'}$ and Y is CR^8R^9W and $n=1$;
- (xii) X is CR^6R^7W and Y is $NHR^{11'}$ or OH and $n=1$;
- (xiii) X is $CR^6R^7SO_2W$ and Y is H and $n=0$;
- (xiv) X is W or OH and Y is CH_2OH and $n=1$;
- 20 (xv) X is $NHR^{11'}$ and Y is SO_2W or X is $NR^{11'}SO_2W$ and Y is H, and $n=0$;
- (xvi) X is $NR^{11'}COCH_2W$ or $NR^{11'}SO_2CH_2W$ and Y is H and $n=0$;
- (xvii) X is W and Y is $CONHR^{11'}$;

in which W is a leaving group, e.g. halo or imidazolyl; R^X and R^Y are (C_{1-6}) alkyl; R^Z is aryl or (C_{1-6}) alkyl; A' and $NR^{11'}$ are A and NR^{11} as defined in formula (I), or groups convertible thereto; and oxirane is:



wherein R^6 , R^8 and R^9 are as defined in formula (I);
30 and thereafter optionally or as necessary converting Q^1 and Q^2 to $NR^{2'}R^{4'}$; converting A', Z^1 , Z^2 , Z^3 , Z^4 , Z^5 , R^1 , R^2 , R^3 , R^4 and $NR^{11'}$ to A, Z^1 , Z^2 , Z^3 , Z^4 , Z^5 , R^1 , R^2 , R^3 , R^4 and $NR^{11'}$; converting A-B to other A-B, interconverting R^1 , R^2 , R^3 and/or R^4 , and/or forming a pharmaceutically acceptable derivative thereof.

35 Process variant (i) initially produces compounds of formula (I) wherein A-B is A'-CO.

Process variant (ii) initially produces compounds of formula (I) wherein A-B is $\text{CHR}^6\text{-CR}^8\text{R}^9$.

Process variant (iii) initially produces compounds of formula (I) wherein A-B is $\text{CR}^6(\text{OH})\text{-CR}^8\text{R}^9$.

5 Process variant (iv) initially produces compounds of formula (I) where A-B is NH-CO .

Process variant (v) initially produces compounds of formula (I) wherein A-B is CO-CH_2 or $\text{CH}_2\text{-CO}$.

10 Process variant (vi) initially produces compounds of formula (I) wherein A-B is $\text{CR}^6\text{R}^7\text{-CR}^9\text{OH}$.

Process variant (vii) and (viii) initially produce compounds of formula (I) wherein A-B is $\text{CR}^7\text{=CR}^9$.

Process variant (ix) initially produces compounds of formula (I) where A-B is CO-NR^{11} or $\text{NR}^{11}\text{-CO}$.

15 Process variant (x) initially produces compounds of formula (I) wherein A-B is $\text{CHR}^6\text{-NR}^{11}$ or $\text{NR}^{11}\text{-CHR}^8$.

Process variant (xi) initially produces compounds of formula (I) wherein A-B is $\text{NR}^{11'}\text{-CR}^8\text{R}^9$.

20 Process variant (xii) initially produces compounds of formula (I) wherein A-B is $\text{CR}^6\text{R}^7\text{-NR}^{11'}$ or $\text{CR}^6\text{R}^7\text{-O}$.

Process variant (xiii) initially produces compounds of formula (I) where A-B is $\text{CR}^6\text{R}^7\text{-SO}_2$.

Process variant (xiv) initially produces compounds of formula (I) wherein A-B is O-CH_2 .

25 Process variant (xv) initially produces compounds where AB is $\text{NR}^{11}\text{SO}_2$.

Process variant (xvi) initially produces compounds of formula (I) where A-B is $\text{NR}^{11'}\text{-CO}$ or $\text{NR}^{11'}\text{-SO}_2$ and $n=1$.

Process variant (xvii) initially produces compounds of formula (I) where A-B is $\text{NR}^{11'}\text{-CO}$.

30 In process variants (i) and (ix) the reaction is a standard amide or urea formation reaction involving e.g.:

1. Activation of a carboxylic acid (e.g. to an acid chloride, mixed anhydride, active ester, O-acyl-isourea or other species), and treatment with an amine (Ogliaruso, M.A.; Wolfe, J.F. in *The Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Acid Derivatives, Pt. 1* (John Wiley and Sons, 1979), pp 442-8; Beckwith, A.L.J. in *The Chemistry of Functional Groups (Ed. Patai, S.) Suppl. B: The Chemistry of Amides (Ed. Zabricky, J.)* (John Wiley and Sons, 1970), p 73 ff. The acid and amide are preferably

35

reacted in the presence of an activating agent such as 1-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or 1-hydroxybenzotriazole (HOBT) or O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HATU); or

2. The specific methods of:

- 5 a. *in situ* conversion of an acid into the amine component by a modified Curtius reaction procedure (Shioiri, T., Murata, M., Hamada, Y., *Chem. Pharm. Bull.* 1987, 35, 2698)
- b. *in situ* conversion of the acid component into the acid chloride under neutral conditions (Villeneuve, G. B.; Chan, T. H., *Tetrahedron. Lett.* 1997, 38, 6489).

A' may be, for example, protected hydroxymethylene.

- 10 The process variant (ii) is a standard addition reaction using methods well known to those skilled in the art. The process is preferably carried out in a polar organic solvent e.g. acetonitrile in the presence of an organic base e.g. triethylamine.

- In process variant (iii) the coupling may be effected in acetonitrile at room temperature in the presence of one equivalent of lithium perchlorate as catalyst (general method of J.E. Chateaufort *et al.*, *J. Org. Chem.*, 56, 5939-5942, 1991) or more
- 15 preferably with ytterbium triflate in dichloromethane. In some cases an elevated temperature such as 40 – 70 °C may be beneficial. Alternatively, the piperidine may be treated with a base, such as one equivalent of butyl lithium, and the resulting salt reacted with the oxirane in an inert solvent such as tetrahydrofuran, preferably at an elevated
- 20 temperature such as 80°C. Use of a chiral epoxide will afford single diastereomers. Alternatively, mixtures of diastereomers may be separated by preparative HPLC or by conventional resolution through crystallisation of salts formed from chiral acids.

- The process variant (iv) is a standard urea formation reaction from the reaction of an isocyanate with an amine and is conducted by methods well known to those skilled in
- 25 the art (for example see March, J; *Advanced Organic Chemistry, Edition 3* (John Wiley and Sons, 1985), p802-3). The process is preferably carried out in a polar solvent such as *N,N*-dimethylformamide.

- In process variant (v) the process is two step: firstly a condensation using a base, preferably sodium hydride or alkoxide, sodamide, alkyl lithium or lithium dialkylamide,
- 30 preferably in an aprotic solvent e.g. ether, THF or benzene; secondly, hydrolysis using an inorganic acid, preferably HCl in aqueous organic solvent at 0-100°C. Analogous routes are described in DE330945, EP31753, EP53964 and H. Sargent, *J. Am. Chem. Soc.* 68, 2688-2692 (1946). Similar Claisen methodology is described in Soszko *et. al.*, *Pr.Kom.Mat. Przyr.Poznan.Tow.Przyj.Nauk.*, (1962), 10, 15.

- 35 In process variant (vi) the reaction is carried out in the presence of a base, preferably organometallic or metal hydride e.g. NaH, lithium diisopropylamide or NaOEt,

preferably in an aprotic solvent, preferably THF, ether or benzene at -78 to 25°C (analogous process in Gutswiller et al. (1978) J. Am. Chem. Soc. 100, 576).

In process variants (vii) and (viii) if a base is used it is preferably NaH, KH, an alkyl lithium e.g. BuLi, a metal alkoxide e.g. NaOEt, sodamide or lithium dialkylamide e.g. diisopropylamide. An analogous method is described in US 3989691 and M. Gates et. al. (1970) J. Amer. Chem. Soc., 92, 205, as well as Taylor et al. (1972) JACS 94, 6218.

In process variant (x) where X or Y is CHO the reaction is a standard reductive alkylation using, e.g., sodium borohydride or sodium triacetoxyborohydride (Gribble, G. W. in *Encyclopedia of Reagents for Organic Synthesis* (Ed. Paquette, L. A.) (John Wiley and Sons, 1995), p 4649).

The process variants (xi) and (xii) are standard alkylation reactions well known to those skilled in the art, for example where an alcohol or amine is treated with an alkyl halide in the presence of a base (for example see March, J; *Advanced Organic Chemistry, Edition 3* (John Wiley and Sons, 1985), p364-366 and p342-343). The process is preferably carried out in a polar solvent such as N,N-dimethylformamide

In process variant (xiii) the reaction is a standard sulphonamide formation reaction well known to those skilled in the art. This may be e.g. the reaction of a sulphonyl halide with an amine.

In process variant (xiv) where X is W such as halogen, methanesulphonyloxy or trifluoromethanesulphonyloxy, the hydroxy group in Y is preferably converted to an OM group where M is an alkali metal by treatment of an alcohol with a base. The base is preferably inorganic such as NaH, lithium diisopropylamide or sodium. Where X is OH, the hydroxy group in Y is activated under Mitsunobu conditions (Fletcher et.al. J Chem Soc. (1995), 623). Alternatively the X=O and Y=CH₂OH groups can be reacted directly by activation with dichlorocarbodiimide (DCC) (Chem. Berichte 1962, 95, 2997 or Angewante Chemie 1963 75, 377).

In process variant (xv) the reaction is conducted in the presence of an organic base such as triethylamine or pyridine such as described by Fuhrman et.al., J. Amer. Chem. Soc.; 67, 1245, 1945. The X=NR^{11'}SO₂W or Y=SO₂W intermediates can be formed from the requisite amine e.g. by reaction with SO₂Cl₂ analogously to the procedure described by the same authors Fuhrman et.al., J. Amer. Chem. Soc.; 67, 1245, 1945.

In process variant (xvi) the reaction is an alkylation, examples of which are described in J. Med. chem. (1979) 22(10) 1171-6. The compound of formula (IV) may be prepared from the corresponding compound where X is NHR^{11'} by acylation with an appropriate derivative of the acid WCH₂COOH such as the acid chloride or sulphonation

with an appropriate derivative of the sulphonic acid WCH_2SO_3H such as the sulphonyl chloride.

In process variant (xvii) the leaving group W is preferably chloro or trifluoromethylsulphonyl and the reaction is the palladium catalysed process known as the "Buchwald" reaction (J. Yin and S. L. Buchwald, *Org.Lett.*, 2000, 2, 1101).

Reduction of a carbonyl group A or B to $CHOH$ can be readily accomplished using reducing agents well known to those skilled in the art, e.g. sodium borohydride in aqueous ethanol or lithium aluminium hydride in ethereal solution. This is analogous to methods described in EP53964, US384556 and J. Gutzwiller *et al*, *J. Amer. Chem. Soc.*, 1978, 100, 576.

The carbonyl group A or B may be reduced to CH_2 by treatment with a reducing agent such as hydrazine in ethylene glycol, at e.g. 130-160°C, in the presence of potassium hydroxide.

Reaction of a carbonyl group A or B with an organometallic reagent yields a group where R^8 is OH and R^9 is alkyl.

A hydroxy group on A or B may be oxidised to a carbonyl group by oxidants well known to those skilled in the art, for example, manganese dioxide, pyridinium chlorochromate or pyridinium dichromate.

A hydroxyalkyl A-B group CHR^7CR^9OH or $CR^7(OH)CHR^9$ may be dehydrated to give the group $CR^7=CR^9$ by treatment with an acid anhydride such as acetic anhydride.


Methods for conversion of $CR^7=CR^9$ by reduction to CHR^7CHR^9 are well known to those skilled in the art, for example using hydrogenation over palladium on carbon as catalyst. Methods for conversion of $CR^7=CR^9$ to give the A-B group $CR^7(OH)CHR^9$ or CHR^7CR^9OH are well known to those skilled in the art for example by epoxidation and subsequent reduction by metal hydrides, hydration, hydroboration or oxymercuration.

An amide carbonyl group may be reduced to the corresponding amine using a reducing agent such as lithium aluminium hydride.

A hydroxy group in A or B may be converted to azido by activation and displacement e.g. under Mitsunobu conditions using hydrazoic acid or by treatment with diphenylphosphorylazide and base, and the azido group in turn may be reduced to amino by hydrogenation.

An example of a group Q^1 convertible to NR^2R^4 is $NR^2R^{4'}$ or halogen. Halogen may be displaced by an amine $HNR^2R^{4'}$ by a conventional alkylation.

When $Q^1 Q^2$ together form a protected oxo group this may be an acetal such as ethylenedioxy which can subsequently be removed by acid treatment to give a compound of formula (VI):



wherein the variables are as described for formula (I)

Intermediates of formula (VI) are novel and as such form part of the invention.

The ketone of formula (VI) is reacted with an amine HNR^2R^4 by conventional reductive alkylation as described above for process variant (x).

Examples of groups $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^4, \text{Z}^5$ convertible to $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^4$ and Z^5 include $\text{CR}^{1a'}$ where $\text{R}^{1a'}$ is a group convertible to R^{1a} . $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^4$ and Z^5 are preferably $\text{Z}^1, \text{Z}^2, \text{Z}^3, \text{Z}^4$ and Z^5 .

$\text{R}^{1a'}, \text{R}^1$ and R^2 are preferably $\text{R}^{1a}, \text{R}^1$ and R^2 . R^1 is preferably methoxy. R^2 is preferably hydrogen. R^3 is R^3 or more preferably hydrogen, vinyl, alkoxycarbonyl or carboxy. R^4 is R^4 or more preferably H or an N-protecting group such as t-butoxycarbonyl, benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl.

Conversions of $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 and interconversions of $\text{R}^1, \text{R}^2, \text{R}^3$ and R^4 are conventional. In compounds which contain an optionally protected hydroxy group, suitable conventional hydroxy protecting groups which may be removed without disrupting the remainder of the molecule include acyl and alkylsilyl groups. N-protecting groups are removed by conventional methods.

For example R^1 methoxy is convertible to R^1 hydroxy by treatment with lithium and diphenylphosphine (general method described in Ireland *et al*, *J. Amer. Chem. Soc.*, 1973, 7829) or HBr. Alkylation of the hydroxy group with a suitable alkyl derivative bearing a leaving group such as halide and a protected amino, piperidyl, amidino or guanidino group or group convertible thereto, yields, after conversion/deprotection, R^1 alkoxy substituted by optionally N-substituted amino, piperidyl, guanidino or amidino.

R^3 alkenyl is convertible to hydroxyalkyl by hydroboration using a suitable reagent such as 9-borabicyclo[3.3.1]nonane, epoxidation and reduction or oxymercuration.

R^3 1,2-dihydroxyalkyl can be prepared from R^3 alkenyl using osmium tetroxide or other reagents well known to those skilled in the art (see *Advanced Organic Chemistry*, Ed. March, J., John Wiley and Sons, 1985, p 732-737 and refs. cited therein) or epoxidation followed by hydrolysis (see *Advanced Organic Chemistry*, Ed. March, J., John Wiley and Sons, 1985, p 332,333 and refs. cited therein).

R^3 vinyl can be chain extended by standard homologation, e.g. by conversion to hydroxyethyl followed by oxidation to the aldehyde, which is then subjected to a Wittig reaction.

Opening an epoxide-containing R^3 group with cyanide anion yields a $CH(OH)-CH_2CN$ group.

Opening an epoxide-containing R^3 group with azide anion yields an α -hydroxy azide derivative which can be reduced to the α -hydroxy amine. Conversion of the α -hydroxy amine to a carbamate is followed by ring closure with base to give the 2-oxo-oxazolidinyl containing R^3 group.

Substituted 2-oxo-oxazolidinyl containing R^3 groups may be prepared from the corresponding aldehyde by conventional reaction with a glycine anion equivalent, followed by cyclisation of the resulting amino alcohol (M. Grauert *et al*, *Ann. Chem.*, 1985, 1817; Rozenberg *et al*, *Angew. Chem. Int. Ed. Engl.*, 1994, 33(1), 91). The resulting 2-oxo-oxazolidinyl group contains a carboxy group which can be converted to other R^{10} groups by standard procedures.

Carboxy groups within R^3 may be prepared by Jones' oxidation of the corresponding alcohols CH_2OH using chromium acid and sulphuric acid in water/methanol (E.R.H. Jones *et al*, *J. Chem. Soc.*, 1946, 39). Other oxidising agents may be used for this transformation such as sodium periodate catalysed by ruthenium trichloride (G.F. Tutwiler *et al*, *J. Med. Chem.*, 1987, 30(6), 1094), chromium trioxide-pyridine (G. Just *et al*, *Synth. Commun.*, 1979, 9(7), 613), potassium permanganate (D.E. Reedich *et al*, *J. Org. Chem.*, 1985, 50(19), 3535), and pyridinium chlorochromate (D. Askin *et al*, *Tetrahedron Lett.*, 1988, 29(3), 277).

The carboxy group may alternatively be formed in a two stage process, with an initial oxidation of the alcohol to the corresponding aldehyde using for instance dimethyl sulphoxide activated with oxalyl chloride (N.Cohen *et al*, *J. Am. Chem. Soc.*, 1983, 105, 3661) or dicyclohexylcarbodiimide (R.M.Wengler, *Angew. Chim. Int. Ed. Eng.*, 1985, 24(2), 77), or oxidation with tetrapropylammonium perruthenate (Ley *et al*, *J. Chem. Soc. Chem Commun.*, 1987, 1625). The aldehyde may then be separately oxidised to the corresponding acid using oxidising agents such as silver (II) oxide (R.Grigg *et al*, *J. Chem. Soc. Perkin I*, 1983, 1929), potassium permanganate (A.Zurcher, *Helv. Chim. Acta.*, 1987, 70 (7), 1937), sodium periodate catalysed by ruthenium trichloride (T.Sakata *et al*, *Bull. Chem. Soc. Jpn.*, 1988, 61(6), 2025), pyridinium chlorochromate (R.S.Reddy *et al*, *Synth. Commun.*, 1988, 18(51), 545) or chromium trioxide (R.M.Coates *et al*, *J. Am. Chem. Soc.*, 1982, 104, 2198).

An R^3 CO_2H group may also be prepared from oxidative cleavage of the corresponding diol, $CH(OH)CH_2OH$, using sodium periodate catalysed by ruthenium

trichloride with an acetonitrile-carbon tetrachloride-water solvent system (V.S. Martin *et al*, *Tetrahedron Letters*, 1988, 29(22), 2701).

Other routes to the synthesis of carboxy groups within R^3 are well known to those skilled in the art.

- 5 R^3 groups containing a cyano or carboxy group may be prepared by conversion of an alcohol to a suitable leaving group such as the corresponding tosylate by reaction with para-toluenesulphonyl chloride (M.R. Bell, *J. Med. Chem.*, 1970, 13, 389), or the iodide using triphenylphosphine, iodine, and imidazole (G. Lange, *Synth. Commun.*, 1990, 20, 1473). The second stage is the displacement of the leaving group with cyanide anion
- 10 (L.A. Paquette *et al*, *J. Org. Chem.*, 1979, 44(25), 4603; P.A. Grieco *et al*, *J. Org. Chem.*, 1988, 53(16), 3658. Finally acidic hydrolysis of the nitrile group gives the desired acids (H. Rosemeyer *et al*, *Heterocycles*, 1985, 23 (10), 2669). The hydrolysis may also be carried out with base e.g. potassium hydroxide (H. Rapoport, *J. Org. Chem.*, 1958, 23, 248) or enzymatically (T. Beard *et al*, *Tetrahedron Asymmetry*, 1993, 4 (6), 1085).

- 15 Other functional groups in R^3 may be obtained by conventional conversions of carboxy or cyano groups.

- Tetrazoles are conveniently prepared by reaction of sodium azide with the cyano group (e.g. F. Thomas *et al*, *Bioorg. Med. Chem. Lett.*, 1996, 6(6), 631; K. Kubo *et al*, *J. Med. Chem.*, 1993, 36, 2182) or by reaction of azidotri-n-butyl stannane with the cyano
- 20 group followed by acidic hydrolysis (P.L. Ornstein, *J. Org. Chem.*, 1994, 59, 7682 and *J. Med. Chem.*, 1996, 39 (11), 2219).

- The 3-hydroxy-3-cyclobutene-1,2-dione-4-yl group (e.g. R.M. Soll, *Bioorg. Med. Chem. Lett.*, 1993, 3(4), 757 and W.A. Kinney, *J. Med. Chem.*, 1992, 35(25), 4720) can be prepared by the following sequence:- (1) a compound where R^3 is $(CH_2)_nCHO$ ($n =$
- 25 0,1,2) is treated with triethylamine, carbon tetrabromide-triphenylphosphine to give initially $(CH_2)_nCH=CHBr$; (2) dehydrobromination of this intermediate to give the corresponding bromoethyne derivative $(CH_2)_nC\equiv CBr$ (for this 2 stage sequence see D. Grandjean *et al*, *Tetrahedron Lett.*, 1994, 35(21), 3529); (3) palladium-catalysed coupling of the bromoethyne with 4-(1-methylethoxy)-3-(tri-n-butylstannyl)cyclobut-3-ene-1,2-
- 30 dione (Liebeskind *et al*, *J. Org. Chem.*, 1990, 55, 5359); (4) reduction of the ethyne moiety to $-CH_2CH_2-$ under standard conditions of hydrogen and palladium on charcoal catalysis (see Howard *et al*, *Tetrahedron*, 1980, 36, 171); and finally (4) acidic hydrolysis of the methyl ethoxyester to generate the corresponding 3-hydroxy-3-cyclobutene-1,2-dione group (R.M. Soll, *Bioorg. Med. Chem. Lett.*, 1993, 3(4), 757).

- 35 The tetrazol-5-ylaminocarbonyl group may be prepared from the corresponding carboxylic acid and 2-aminotetrazole by dehydration with standard peptide coupling

agents such as 1,1'-carbonyldiimidazole (P.L. Ornstein *et al*, *J. Med Chem*, 1996, 39(11), 2232).

The alkyl- and alkenyl-sulphonylcarboxamides are similarly prepared from the corresponding carboxylic acid and the alkyl- or alkenyl-sulphonamide by dehydration
5 with standard peptide coupling agents such as 1,1'-carbonyldiimidazole (P.L. Ornstein *et al*, *J. Med. Chem.*, 1996, 39(11), 2232).

The hydroxamic acid groups are prepared from the corresponding acids by standard amide coupling reactions e.g. N.R. Patel *et al*, *Tetrahedron*, 1987, 43(22), 5375.

2,4-Thiazolidinedione groups may prepared from the aldehydes by condensation
10 with 2,4-thiazolidinedione and subsequent removal of the olefinic double bond by hydrogenation.

The preparation of 5-oxo-1,2,4-oxadiazoles from nitriles is described by Y. Kohara *et al*, *Bioorg. Med. Chem. Lett.*, 1995, 5(17), 1903.

1,2,4-Triazol-5-yl groups may be prepared from the corresponding nitrile by
15 reaction with an alcohol under acid conditions followed by reaction with hydrazine and then an R¹⁰-substituted activated carboxylic acid (see J.B. Polya in "Comprehensive Heterocyclic Chemistry" Edition 1, p762, Ed A.R. Katritzky and C.W. Rees, Pergamon Press, Oxford, 1984 and J.J. Ares *et al*, *J. Heterocyclic Chem.*, 1991, 28(5), 1197).

Other substituents on R³ alkyl or alkenyl may be interconverted by conventional
20 methods, for example hydroxy may be derivatised by esterification, acylation or etherification. Hydroxy groups may be converted to halogen, thiol, alkylthio, azido, alkylcarbonyl, amino, aminocarbonyl, oxo, alkylsulphonyl, alkenylsulphonyl or aminosulphonyl by conversion to a leaving group and substitution by the required group or oxidation as appropriate or reaction with an activated acid, isocyanate or
25 alkoxyisocyanate. Primary and secondary hydroxy groups can be oxidised to an aldehyde or ketone respectively and alkylated with a suitable agent such as an organometallic reagent to give a secondary or tertiary alcohol as appropriate. A carboxylate group may be converted to a hydroxymethyl group by reduction of an ester of this acid with a suitable reducing agent such as LiAlH₄.

30 An NH₂ substituent on piperidine is converted to NR²R⁴ by conventional means such as amide or sulphonamide formation with an acyl derivative R⁵COW or R⁵SO₂W, for compounds where U is CO or SO₂ or, where U is CH₂, alkylation with an alkyl halide R⁵CH₂-halide in the presence of base, acylation/reduction with an acyl derivative R⁵COW or reductive alkylation with an aldehyde R⁵CHO.

35 Where one of R³ and R⁶, R⁷, R⁸ or R⁹ contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage. This linkage may form spontaneously during coupling of the compound of

formula (IV) and the piperidine moiety or in the presence of standard peptide coupling agents.

It will be appreciated that under certain circumstances interconversions may interfere, for example, A or B hydroxy groups in A or B and the piperidine substituent NH₂ will require protection e.g. as a carboxy- or silyl-ester group for hydroxy and as an acyl derivative for piperidine NH₂, during conversion of R^{1'}, R^{2'}, R^{3'} or R^{4'}, or during the coupling of the compounds of formulae (IV) and (V).

Compounds of formulae (IV) and (V) are known compounds, (see for example Smith *et al*, *J. Amer. Chem. Soc.*, 1946, 68, 1301) or prepared analogously.

Compounds of formula (IV) where X is CR⁶R⁷SO₂W may be prepared by a route analogous to that of Ahmed El Hadri *et al*, *J. Heterocyclic Chem.*, 1993, 30(3), 631. Thus compounds of formula (IV) where X is CH₂SO₂OH may be prepared by reacting the corresponding 4-methyl compound with N-bromosuccinimide, followed by treatment with sodium sulfite. The leaving group W may be converted to another leaving group W, e.g. a halogen group, by conventional methods.

The isocyanate of formula (IV) may be prepared conventionally from a 4-amino derivative such as 4-amino-quinoline, and phosgene, or phosgene equivalent (eg triphosgene) or it may be prepared more conveniently from a 4-carboxylic acid by a "one-pot" Curtius Reaction with diphenyl phosphoryl azide (DPPA) [see T. Shiori *et al*. *Chem. Pharm. Bull.* 35, 2698-2704 (1987)].

The 4-amino derivatives are commercially available or may be prepared by conventional procedures from a corresponding 4-chloro or 4-trifluoromethanesulphonate derivative by treatment with ammonia (O.G. Backeberg *et. al.*, *J. Chem Soc.*, 381, 1942) or propylamine hydrochloride (R. Radinov *et. al.*, *Synthesis*, 886, 1986).

4-Alkenyl compounds of formula (IV) may be prepared by conventional procedures from a corresponding 4-halogeno-derivative by e.g. a Heck synthesis as described in e.g. *Organic Reactions*, 1982, 27, 345.

4-Halogeno derivatives of compounds of formula (IV) are commercially available, or may be prepared by methods known to those skilled in the art. A 4-chloroquinoline is prepared from the corresponding quinolin-4-one by reaction with phosphorus oxychloride (POCl₃) or phosphorus pentachloride, PCl₅. A 4-chloroquinazoline is prepared from the corresponding quinazolin-4-one by reaction with phosphorus oxychloride (POCl₃) or phosphorus pentachloride, PCl₅. A quinazolinone and quinazolines may be prepared by standard routes as described by T.A. Williamson in *Heterocyclic Compounds*, 6, 324 (1957) Ed. R.C. Elderfield.

Activated carboxy derivatives $X=A'COW$ of formula (IV) may be prepared from $X=A'CO_2H$ derivatives in turn prepared from CO_2H derivatives by conventional methods such as homologation.

4-Carboxy derivatives of compounds of formula (IV) are commercially available
5 or may be prepared by conventional procedures for preparation of carboxy
heteroaromatics well known to those skilled in the art. For example, quinazolines may be
prepared by standard routes as described by T.A. Williamson in *Heterocyclic
Compounds*, 6, 324 (1957) Ed. R.C. Elderfield. These 4-carboxy derivatives may be
activated by conventional means, e.g. by conversion to an acyl halide or anhydride.

10 Pyridazines may be prepared by routes analogous to those described in
Comprehensive Heterocyclic Chemistry, Volume 3, Ed A.J. Boulton and A. McKillop
and naphthyridines may be prepared by routes analogous to those described in
Comprehensive Heterocyclic Chemistry, Volume 2, Ed A.J. Boulton and A. McKillop.

A 4-oxirane derivative of compounds of formula (IV) is conveniently prepared
15 from the 4-carboxylic acid by first conversion to the acid chloride with oxalyl chloride
and then reaction with trimethylsilyldiazomethane to give the diazoketone derivative.
Subsequent reaction with 5M hydrochloric acid gives the chloromethylketone. Reduction
with sodium borohydride in aqueous methanol gives the chlorohydrin which undergoes
ring closure to afford the epoxide on treatment with base, e.g. potassium hydroxide in
20 ethanol-tetrahydrofuran.

Alternatively and preferably, 4-oxirane derivatives can be prepared from
bromomethyl ketones which can be obtained from 4-hydroxy compounds by other routes
well known to those skilled in the art. For example, hydroxy compounds can be converted
to the corresponding 4-trifluoromethanesulphonates by reaction with
25 trifluoromethanesulphonic anhydride under standard conditions (see K. Ritter, *Synthesis*,
1993, 735). Conversion into the corresponding butyloxyvinyl ethers can be achieved by a
Heck reaction with butyl vinyl ether under palladium catalysis according to the procedure
of W. Cabri *et al*, *J. Org. Chem.*, 1992, 57 (5), 1481. (Alternatively, the same
intermediates can be attained by Stille coupling of the trifluoromethanesulphonates or the
30 analogous chloro derivatives with (1-ethoxyvinyl)tributyl tin, T. R. Kelly, *J. Org. Chem.*,
1996, 61, 4623.) The alkyloxyvinyl ethers are then converted into the corresponding
bromomethylketones by treatment with N-bromosuccinimide in aqueous tetrahydrofuran
in a similar manner to the procedures of J. F. W. Keana, *J. Org. Chem.*, 1983, 48, 3621
and T. R. Kelly, *J. Org. Chem.*, 1996, 61, 4623.

35 The 4-hydroxyderivatives can be prepared from an aminoaromatic by reaction
with methylpropiolate and subsequent cyclisation, analogous to the method described in

N. E. Heindel et al, *J. Het. Chem.*, 1969, 6, 77. For example, 5-amino-2-methoxy pyridine can be converted to 4-hydroxy-6-methoxy-[1,5]naphthyridine using this method.

If a chiral reducing agent such as (+) or (-)-B-chlorodiisopinocampheylborane ['DIP-chloride'] is substituted for sodium borohydride, the prochiral chloromethylketone is converted into the chiral chlorohydrin with ee values generally 85-95% [see C. Bolm et al, *Chem. Ber.* 125, 1169-1190, (1992)]. Recrystallisation of the chiral epoxide gives material in the mother liquor with enhanced optical purity (typically ee 95%).

The (*R*)-epoxide, when reacted with a piperidine derivative gives ethanolamine compounds as single diastereomers with (*R*)-stereochemistry at the benzylic position.

Alternatively, the epoxide may be prepared from the 4-carboxaldehyde by a Wittig approach using trimethylsulfonium iodide [see G.A. Epling and K-Y Lin, *J. Het. Chem.*, 1987, 24, 853-857], or by epoxidation of a 4-vinyl derivative.

4-Hydroxy-1,5-naphthyridines can be prepared from 3-aminopyridine derivatives by reaction with diethyl ethoxymethylene malonate to produce the 4-hydroxy-3-carboxylic acid ester derivative with subsequent hydrolysis to the acid, followed by thermal decarboxylation in quinoline (as for example described for 4-Hydroxy-[1,5]naphthyridine-3-carboxylic acid, J. T. Adams et al., *J. Amer. Chem. Soc.*, 1946, 68, 1317). A 4-hydroxy-[1,5]naphthyridine can be converted to the 4-chloro derivative by heating in phosphorus oxychloride, or to the 4-methanesulphonyloxy or 4-trifluoromethanesulphonyloxy derivative by reaction with methanesulphonyl chloride or trifluoromethanesulphonic anhydride, respectively, in the presence of an organic base. A 4-amino 1,5-naphthyridine can be obtained from the 4-chloro derivative by reaction with *n*-propylamine in pyridine.

Similarly, 6-methoxy-1,5-naphthyridine derivatives can be prepared from 3-amino-6-methoxypyridine.

1,5-Naphthyridines may be prepared by other methods well known to those skilled in the art (for examples see P.A. Lowe in "Comprehensive Heterocyclic Chemistry" Volume 2, p581-627, Ed A.R. Katritzky and C.W. Rees, Pergamon Press, Oxford, 1984).

The 4-hydroxy and 4-amino-cinnolines may be prepared following methods well known to those skilled in the art [see A.R. Osborn and K. Schofield, *J. Chem. Soc.* 2100 (1955)]. For example, a 2-aminoacetophenone is diazotised with sodium nitrite and acid to produce the 4-hydroxycinnoline with conversion to chloro and amino derivatives as described for 1,5-naphthyridines.

For compounds of formula (V), suitable amines may be prepared from the corresponding 4-substituted piperidine acid or alcohol. In a first instance, an *N*-protected piperidine containing an acid bearing substituent, can undergo a Curtius rearrangement and the intermediate isocyanate can be converted to a carbamate by reaction with an

alcohol. Conversion to the amine may be achieved by standard methods well known to those skilled in the art used for amine protecting group removal. For example, an acid substituted N-protected piperidine can undergo a Curtius rearrangement e.g. on treatment with diphenylphosphoryl azide and heating, and the intermediate isocyanate reacts in the presence of 2-trimethylsilylethanol to give the trimethylsilylethylcarbamate (T.L. Capson & C.D. Poulter, *Tetrahedron Lett.*, 1984, 25, 3515). This undergoes cleavage on treatment with tetrabutylammonium fluoride to give the 4-amine substituted N-protected piperidine.

In a second instance, an N-protected piperidine containing an alcohol bearing substituent undergoes a Mitsunobu reaction (for example as reviewed in Mitsunobu, *Synthesis*, (1981), 1), for example with succinimide in the presence of diethyl azodicarboxylate and triphenylphosphine to give the phthalimidoethylpiperidine. Removal of the phthaloyl group, for example by treatment with methylhydrazine, gives the amine of formula (V).

R^5CH_2 -halides, acyl derivative R^5COW and R^5SO_2W or aldehydes R^5CHO are commercially available or are prepared conventionally. The aldehydes may be prepared by partial reduction of the R^5 -ester with lithium aluminium hydride or diisobutylaluminium hydride or more preferably by reduction to the alcohol, with lithium aluminium hydride or sodium borohydride, followed by oxidation to the aldehyde with manganese (II) dioxide. The aldehydes may also be prepared from carboxylic acids in two stages by conversion to a mixed anhydride for example by reaction with isobutyl chloroformate followed by reduction with sodium borohydride (R. J. Alabaster et al., *Synthesis*, 598, 1989) to give the hydroxymethyl substituted heteroaromatic or aromatic, and then oxidation with a standard oxidising agent such as pyridinium dichromate or manganese (II) dioxide. Acyl derivative R^5COW may be prepared by activation of the R^5 -acid. R^5CH_2 -halides such as bromides may be prepared from the alcohol R^5CH_2OH by reaction with phosphorus tribromide in DCM/triethylamine. Alternatively the aldehyde R^5CHO and sulphonic acid derivative R^5SO_2W may be generated by treatment of the R^5H heterocycle with suitable reagents. For example by formylation with hexamine in either trifluoroacetic acid or methanesulphonic acid, in a modified Duff procedure [O. I. Petrov et al. *Collect. Czech. Chem. Commun.* 62, 494-497 (1997)]. Reaction of a R^5H heterocycle with chlorosulphonic acid gives the sulphonic acid derivative (by methods analogous to Techer et. al., *C.R.Hebd. Seances Acad. Sci. Ser. C*; 270, 1601, 1970)..

R^5 heterocycles are commercially available or may be prepared by conventional methods.

The amines R^2R^4NH are available commercially or prepared conventionally. For example amines $R^5CH_2NH_2$ may be prepared from a bromomethyl derivative by reaction

with sodium azide in dimethylformamide (DMF), followed by hydrogenation of the azidomethyl derivative over palladium-carbon. An alternative method is to use potassium phthalimide/DMF to give the phthalimidomethyl derivative, followed by reaction with hydrazine in DCM to liberate the primary amine.

- 5 Conversions of R^{1a'}, R^{1'}, R^{2'}, R^{3'} and R^{4'} may be carried out on the intermediates of formulae (IV), and (V) prior to their reaction to produce compounds of formula (I) in the same way as described above for conversions after their reaction.

Further details for the preparation of compounds of formula (I) are found in the examples.

- 10 The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds of formula (I). Libraries of compounds of formula (I) may be prepared by a combinatorial "split and mix" approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

- 15 Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I) or pharmaceutically acceptable derivatives thereof.

Novel intermediates of formulae (IV) and (V) are also part of this invention.

- 20 The antibacterial compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibacterials.

The pharmaceutical compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.

- 25 The composition may be formulated for administration by any route. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

- 30 The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

- 35 The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup,

acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The
5 tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid
10 preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate
15 or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the
20 vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be
25 frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by
30 filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the
35 compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route

and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

No toxicological effects are indicated when a compound of formula (I) or a pharmaceutically acceptable derivative thereof is administered in the above-mentioned

5 dosage range.

The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibacterials. If the other antibacterial is a β -lactam then a β -lactamase inhibitor may also be employed.


Compounds of formula (I) are active against a wide range of organisms including
10 both Gram-negative and Gram-positive organisms.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

15 The following examples illustrate the preparation of certain compounds of formula (I) and the activity of certain compounds of formula (I) against various bacterial organisms.

EXAMPLES

Example 1 (R)-2-{4-[(1H-Indol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate.



5

(a) 6-Methoxyquinoline-4-carboxylic acid

The title compound was prepared by modification of the procedure described by W.E. Doering and J.D. Chanley, *J. Amer. Chem. Soc.*, 1946, 68, 586. A mixture of quinone (derived from quinine by reaction with potassium *tert*-butoxide and benzophenone in toluene) (225g, 0.70 mol), *tert*-butanol (1 litre) and water (10 ml) was treated with potassium *tert*-butoxide (170g, 1.5 mol). The mixture was stirred at 30°C, while air was bubbled through for 3 days. The mixture was diluted with diethyl ether and water and the layers separated. The aqueous phase was extracted with ethyl acetate. The combined diethyl ether and ethyl acetate extracts were dried over magnesium sulfate and evaporated to give recovered starting material (approximately 100g). The aqueous phase was acidified to pH5 with 5M hydrochloric acid. The precipitate was collected by filtration, washed with water and methanol, then dried to give 6-methoxyquinoline-4-carboxylic acid as a yellow solid (64.6g, 46%).

δ H (d-6 DMSO) 6.23-5.95 (1H, m), 5.34-5.06 (2H, m), 3.37-2.92 (5H, m), 2.70 (1H, m), 2.38-2.15 (3H, m), 1.94-1.52 (2H, m)

(b) [R]-2-(6-Methoxyquinolin-4-yl)oxirane

A solution of 6-methoxyquinoline-4-carboxylic acid (10g) in dichloromethane was heated under reflux with oxalyl chloride (5ml) and dimethylformamide (2 drops) for 1 hour and evaporated to dryness. The residue, in dichloromethane (100ml) was treated with a 2M solution of trimethylsilyldiazomethane in hexane (50ml) and stirred at room temperature for 18 hours. 5M Hydrochloric acid (150ml) was added and the solution was stirred at room temperature for 3 hours. It was basified with sodium carbonate solution, extracted with ethyl acetate and chromatographed on silica gel eluting with ethyl acetate-hexane to give the chloromethyl ketone (4.2g). A batch of the chloromethyl ketone (20g) was reduced with (+)-B-chlorodiisopinocampheylborane (40g) in dichloromethane (400ml) at room temperature for 18 hours followed by treatment with diethanolamine (30 g) for 3 hours. The product was chromatographed on silica gel eluting with ethyl acetate-hexane to give the chloroalcohol (16.8g), which was dissolved in tetrahydrofuran (100 ml) and reacted with sodium hydroxide (2.6g) in water (13ml) for 1.5 hours. The reaction

mixture was evaporated to dryness and chromatographed on silica gel eluting with ethyl acetate - hexane to give the title compound as a solid (10.4 g) (84% ee by chiral HPLC). Recrystallisation from ether-pentane gave mother-liquor (7.0 g) (90% ee).

MS (+ve ion electrospray) m/z 202 (MH⁺)

- 5 The absolute stereochemistry was defined to be (R) by an NMR study on the Mosher's esters derived from the product obtained by reaction with 1-t-butylpiperazine.

(c) 4-*tert*-Butoxycarbonylamino-1-[2-(R)-hydroxy-2-(6-methoxyquinolin-4-yl)]ethylpiperidine.

- To a stirred solution of [R]-2-(6-methoxyquinolin-4-yl)oxirane (Example 1b)
10 (8.07g, 40.3 mmol) and lithium perchlorate (4.44g, 40.3 mmol) in anhydrous N,N-dimethylformamide (100mL) was added 4-*tert*-butoxycarbonylamino-1-piperidine hydrochloride (11.0g, 45.7 mmol) and potassium carbonate (6.72g, 48.4 mmol). The mixture was heated at 90°C for 26h, then cooled, filtered and evaporated. The residue was dissolved in ethyl acetate, washed with water, dried and evaporated. The crude product
15 was chromatographed on silica gel eluted with 2-5% methanol/ dichloromethane to give a gum (11.11g).

MS (+ve ion electrospray) m/z 402 (MH⁺).

(d) 4-Amino-1-[2-(R)-hydroxy-2-(6-methoxyquinolin-4-yl)]ethylpiperidine.

- The *tert*-butoxycarbonylamino compound (1c) (11.11g, 27.7 mmol) was dissolved
20 in dichloromethane (30mL), cooled in ice and treated with trifluoroacetic acid (30mL). The solution was stirred at room temperature for 1.5h, then evaporated *in vacuo*. After addition of toluene (50mL) and re-evaporation, the residue was treated with a 4M solution of hydrogen chloride in 1,4-dioxan (30mL). The resulting solid was triturated, filtered off and washed with ether. This was then recrystallised by dissolving in hot methanol,
25 concentrating the solution and diluting with dichloromethane, to give the trihydrochloride salt (9.4g). This was dissolved in water, basified to pH9 and evaporated to dryness. The residue was extracted several times with 10% methanol/ dichloromethane (total 600mL). The extracts were filtered and evaporated to give the free base as a semi-solid foam (6.45g).

- 30 MS (+ve ion electrospray) m/z 302 (MH⁺).

(e) Title compound

- A solution of amine (1d) (50 mg, 0.17 mmol) in dichloromethane (1 ml) was treated with 1H indole-2-carboxaldehyde (0.17 mmol) and sodium triacetoxyborohydride (37 mg, 0.18 mmol). After 16h the reaction mixture was diluted with methanol (1 ml)
35 and sodium borohydride added (70 mg). After 0.5 h the mixture was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The dichloromethane extract was dried and evaporated. The residue was chromatographed on

silica eluting with a methanol/dichloromethane gradient affording the title compound as an oil (24 mg, 33%). A solution of this material in deuteriochloroform (2 ml) was treated with a solution of oxalic acid (15 mg) in ether (10 ml). The resulting precipitate was centrifuged, then washed by resuspending in ether and centrifuging again. Drying *in*


5 *vacuo* afforded the title compound as the dioxalate salt (30 mg).

δ H (d6-DMSO-oxalate salt): 1.95 (2H, m), 2.25 (2H, m), 2.95 (2H, m), 3.10-3.30 (3H, m), 3.65 (2H, m), 3.95 (3H, s), 4.40 (2H, s), 5.80 (1H, dd), 7.45 (2H, m), 7.65 (2H, m), 7.80 (1H, t), 7.95-8.10 (1H, t), 8.50 (1H, s), 8.80 (1H, d), 9.05 (1H, s)

MS (+ve ion electrospray) m/z 431 (MH⁺).

10

Example 2 (R)-2-{4-[(Quinolin-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate



15

This was prepared from amine (1d) and quinoline-2-carboxaldehyde by the same procedure as Example (1e) affording the title compound as an oil (26 mg, 35%). This was converted to the dioxalate (25 mg) in the same way as for Example 1.


δ H (CDCl₃ – free base): 8.78 (1H, d), 8.10 (3H, m), 7.80 (1H, d), 7.60 (1H, t), 7.55 (1H, d), 7.50 (1H, d), 7.45 (1H, d), 7.35 (1H, dd), 7.15 (1H, d), 5.45 (1H, dd), 4.15 (2H, s), 3.90 (3H, s), 3.30 (1H, m), 2.85 (2H, m), 2.70 (1H, m), 2.45 (2H, m), 2.25 (1H, m), 2.05 (2H, m), 1.60 (2H, m).

20

MS (+ve ion electrospray) m/z 443 (MH⁺).

Example 3 (R)-2-{4-[(Benzofuran-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate

25




This was prepared from amine (1d) and benzofuran-2-carboxaldehyde by the same procedure as Example (1e) affording the title compound as an oil (25 mg, 34%). This was converted to the dioxalate (32 mg) in the same way as for Example 1.

δ H (d6-DMSO – dioxalate salt): 1.95 (2H, m), 2.25 (2H, m), 2.95 (2H, m), 3.10-3.30 (3H, m), 3.65 (2H, m), 3.95 (3H, s), 4.35 (2H, s), 5.80 (1H, dd), 7.05 (1H, s), 7.25-7.40 (2H, m), 7.45-7.50 (2H, m), 7.55-7.70 (3H, m), 7.95 (1H, d), 8.75 (1H, d)
MS (+ve ion electrospray) m/z 432 (MH⁺).

5

Example 4 (R)-2-{4-[(Quinolin-3-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate




This was prepared from amine (1d) and quinoline-3-carboxaldehyde by the same procedure as Example (1e) affording the title compound as an oil (26 mg, 35%). This was converted to the dioxalate (30 mg) in the same way as for Example 1.

δ H (d6-DMSO – dioxalate salt): 1.95 (2H, m), 2.25 (2H, m), 2.95 (2H, m), 3.10-3.30 (3H, m), 3.65 (2H, m), 3.95 (3H, s), 4.40 (2H, s), 5.80 (1H, dd), 7.45 (2H, m), 7.65 (2H, m), 7.80 (1H, t), 7.95-8.10 (3H, m), 8.50 (1H, s), 8.80 (1H, d), 9.05 (1H, s)
MS (+ve ion electrospray) m/z 443 (MH⁺).

15

Example 5 (R)-2-{4-[(3-Chloro-benzothiophen-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate



20


This was prepared from amine (1d) and 3-chlorobenzothiophene-2-carboxaldehyde by the same procedure as Example (1e) affording the title compound as an oil (28 mg, 34%). This was converted to the dioxalate (36 mg) in the same way as for Example 1.

δ H (d6-DMSO – dioxalate salt): 1.95 (2H, m), 2.25 (2H, m), 2.95 (2H, m), 3.10-3.30 (3H, m), 3.65 (2H, m), 3.95 (3H, s), 4.35 (2H, s), 5.85 (1H, dd), 7.30 (4H, m), 7.65 (1H, d), 7.80 (1H, d), 8.00 (1H, d), 8.05 (1H, dd), 8.78 (1H, d).
MS (+ve ion electrospray) m/z 482, 484 (MH⁺).

25

Example 6 (R)-2-{4-[(Benzofuran-2-ylmethyl)-amino]-4-hydroxymethyl-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate

30



(a) Allyl 4-benzyloxycarbonylaminopiperidine-4-carboxylate.

- 4-Amino-1-*tert*-butoxycarbonylpiperidine-4-carboxylic acid (18.0g) was dissolved in 0.03M aqueous sodium hydroxide (750 mL), and 1,2-dimethoxyethane (100mL). The pH was adjusted to 9.5 with dilute hydrochloric acid, and the suspension was added to an ice-cold solution of N-(benzyloxycarbonyloxy)succinimide (28.8g) in 1,2-dimethoxyethane (100 mL). The pH was kept at 9.5 by addition of aq. sodium hydroxide, and the mixture was stirred at room temperature. More N-(benzyloxycarbonyloxy)succinimide (3g) was added after 7h, then stirring continued overnight. After evaporation to remove the 1,2-dimethoxyethane, the aqueous residue was extracted with ether then acidified to pH4 and extracted with ethyl acetate. This extract was washed with dilute hydrochloric acid, water and brine, dried and evaporated. Trituration of the oily residue gave 4-benzyloxycarbonylamino-1-*tert*-butoxycarbonylpiperidine-4-carboxylic acid (23g). This acid (9.62g) was esterified by treatment with allyl bromide (2.2mL), potassium carbonate (7.04g) and potassium iodide (catalytic) in acetone (100mL) under reflux for 20h. Evaporation, partitioning of the residue between dichloromethane and water and evaporation of the organic phase gave the allyl ester (10.2g). This was then treated with trifluoroacetic acid in dichloromethane (1.5h, room temp.) to give, after basification of the triflate salt and extraction with dichloromethane/methanol, the piperidine free base (6.58g).

MS (+ve ion electrospray) m/z 319 (MH⁺)

(b) 4-Benzyloxycarbonylamino-1-[(R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-piperidine-4-carboxylic acid, allyl ester

- A solution of piperidine (6a) (1.85g, 5.8 mmol) and epoxide (1b) (1.2g, 5.8 mmol) in acetonitrile (10 mL) was treated with lithium perchlorate (0.62g, 5.8 mmol) and stirred at room temperature for 20h. The mixture was evaporated and the residue partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The dichloromethane extract was dried and evaporated to give an oil. Chromatography on silica eluting with a methanol/dichloromethane gradient afforded the title compound as an oil (1.6g).

MS (+ve ion electrospray) m/z 520 (MH⁺).

(c) 4-Amino-1-[(R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-piperidine-4-carboxylic acid, propyl ester

A solution of (6b) (1.58g) in ethanol (100 ml) was hydrogenated over 10% palladium on charcoal (0.1g) for 16h. Filtration, evaporation, and chromatography on silica eluting with a methanol/dichloromethane gradient afforded the title compound as an oil (0.53g).

5 MS (+ve ion electrospray) m/z 388 (MH+).

(d) (R)-2-(4-Amino-4-hydroxymethylpiperidin-1-yl)-1-(6-methoxyquinolin-4-yl)-ethanol

A solution of ester (6c) (0.52 g, 1.3 mmol) in tetrahydrofuran (8 ml) was treated at 0°C with a solution of lithium aluminium hydride in tetrahydrofuran (1M; 1.4 ml, 1.4 mmol). After 1h aqueous sodium hydroxide (2M, 20 ml) was added and the mixture was
10 extracted with dichloromethane (30 ml). Drying, evaporation, and chromatography on silica eluting with a methanol/dichloromethane gradient afforded the product as an oil (0.24g).


MS (+ve ion electrospray) m/z 332 (MH+).

(e) Title compound

15 A solution of the amine (6d) (50 mg) and benzofuran-2-carboxaldehyde (22 mg) in dichloromethane (2 ml) was treated with sodium triacetoxyborohydride (42 mg). After 0.5h methanol (1 ml) was added followed by sodium borohydride (20 mg). The mixture was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The dichloromethane extract was dried and evaporated to give an oil.
20 Chromatography on silica eluting with a methanol/dichloromethane gradient afforded the title compound as an oil (55 mg). This was converted to the dioxalate salt (65 mg) by the same procedure as for Example 1.

δ H (CDCl₃ – free base): 2.05 (2H, m), 2.60-2.80 (4H, m), 2.85-3.10 (2H, m), 3.50 (2H, s), 3.85 (2H, 2), 3.95 (3H, s), 5.55 (1H, dd), 6.55 (1H, s), 7.15-7.30 (4H, m), 7.35-7.45
25 (2H, m), 7.52 (1H, m), 7.65 (1H, d), 8.05 (1H, d), 8.80 (1H, d)
MS (+ve ion electrospray) m/z 462 (MH+).

Example 7 (R)-2-{4-[(1H-Benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate



30

(a) (R)-2-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-1-(6-methoxyquinolin-4-yl)-ethanol

[R]-2-(6-Methoxyquinolin-4-yl)oxirane (1b) (470 mg) and 1,4-dioxa-8-azaspiro-[4,5]-decane (0.33 ml) were dissolved in dry dichloromethane (5 ml) and ytterbium

triflate (30 mol%) was added. The mixture was stirred for 6 hours, filtered through celite, evaporated and chromatographed on silica gel (dichloromethane then methanol-dichloromethane) to afford the title compound (690 mg).

MS (+ve ion electrospray) m/z 345 (MH⁺).

5 (b) 1-[(R)-2-Hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-4-one

The acetal (7a) was cleaved by treatment with 5M hydrochloric acid (10 ml) in acetone (20 ml) at 60 °C overnight. The mixture was basified with sodium bicarbonate solution and concentrated. Extraction into dichloromethane, evaporation and chromatography on silica gel (dichloromethane then methanol-dichloromethane) gave a yellow gum (482 mg) which solidified on standing. Recrystallisation from boiling ethyl acetate/hexane afforded the product as a pale yellow solid (220 mg), which by chiral hplc
10 was shown to have an enantiomeric excess of >98%.

(c) Title compound


A mixture of the ketone (7b) (0.1 g), 2-aminomethylbenzimidazole
15 dihydrochloride salt (73 mg), diisopropylethylamine (45 mg), and 3A molecular sieves (0.1 g) in methanol (3 ml) was treated with sodium triacetoxyborohydride (0.18 g) and stirred for 16h. The mixture was filtered and evaporated. The residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The dichloromethane extract was dried and evaporated to give an oil. Chromatography on
20 silica eluting with a methanol/dichloromethane gradient afforded the title compound as an oil (55 mg). This was converted to the dioxalate salt (70 mg) by the same procedure as for Example 1.

δ H (CDCl₃ – free base) : 1.50 (2H, m), 2.00 (2H, m), 2.1-2.6 (4H, m), 2.80 (2H, m), 3.25 (1H, m), 3.90 (3H, s), 4.20 (2H, s), 5.40 (1H, dd), 7.15 (1H, d), 7.25 (2H, m), 7.35 (1H, dd), 7.60 (3H, m), 8.05 (1H, d), 8.80 (1H, d)
25

MS (+ve ion electrospray) m/z 432 (MH⁺).

Example 8 3-([1-[(R)-2-Hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-piperidin-4-ylamino]-methyl)-chromen-4-one, dioxalate


30



This compound (43 mg) was prepared from amine (1d) 4-oxo-4H-chromene-3-carboxaldehyde by the same procedure as for Example (1e).

MS (+ve ion electrospray) m/z 460 (MH⁺).


Example 9 (R)-2-{4-[(5-Bromo-1H-indol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol, dioxalate



5 This compound (14 mg) was prepared from amine (1d) and 5-bromo-1H-indole-2-carboxaldehyde by the same procedure as for Example (1e)

MS (+ve ion electrospray) m/z 509 (MH⁺).


10 **Example 10 (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(1-methyl-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol, dioxalate**



This compound (43mg) was prepared from amine (1d) and 1-methyl-1H-benzimidazole-2-carboxaldehyde by the same procedure as for Example (1e)

15 MS (+ve ion electrospray) m/z 446 (MH⁺).

Example 11 (R)-2-{4-[(6-Methoxy-benzothiazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol, dioxalate




20

This compound (43mg) was prepared from amine (1d) and 6-methoxy-benzothiazole-2-carboxaldehyde by the same procedure as for Example (1e).

MS (+ve ion electrospray) m/z 479 (MH⁺).

25 **Example 12 (R)-2-{4-[(4,6-Difluoro-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate**



(a) (4,6-Difluoro-1H-benzimidazol-2-yl)-methylamine

A mixture of glycine (2.0g) and 3,5-difluoro-benzene-1,2-diamine in 5M hydrochloric acid (5mL) was heated under reflux for 18 hours and evaporated. Sodium carbonate solution was added to pH 10 and the solution was extracted with dichloromethane. The aqueous fraction was evaporated to dryness and the residue was extracted with 5% methanol in chloroform, dried and evaporated to give a foam (0.6g). MS (+ve ion electrospray) m/z 184 (MH⁺).

(b) Title compound

This was prepared from the amine (12a) (52mg) and ketone (7b) (0.085g), by the method of Example (7c) to afford the title compound as an oil (63 mg).

MS (+ve ion electrospray) m/z 468 (MH⁺).

¹H NMR (CDCl₃) δ: 1.50 (2H, m), 2.00 (2H, m), 2.1-2.6 (4H, m), 2.80 (2H, m), 3.25 (1H, m), 3.90 (3H, s), 4.20 (2H, s), 5.40 (1H, dd), 6.75 (1H, brt), 7.05 (1H, br d), 7.15 (1H, d), 7.25, 7.35 (1H, dd), 7.60 (1H, d), 8.05 (1H, d), 8.80 (1H, d)

This was converted to the dioxalate salt (78 mg) by the same procedure as for Example 1.


The following compounds (13-15) were prepared by the method of Example 12

Example 13 (R)-2-{4-[(4,5-Difluoro-1H-benzimidazol-2-yl)methyl]-amino}-piperidin-1-yl-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate MS (+ve ion electrospray) m/z 468 (MH⁺).

Example 14 (R)-2-{4-[(5,6-Difluoro-1H-benzimidazol-2-yl)methyl]-amino}-piperidin-1-yl-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate MS (+ve ion electrospray) m/z 468 (MH⁺).

Example 15 (R)-2-{4-[(5-Fluoro-1H-benzimidazol-2-yl)methyl]-amino}-piperidin-1-yl-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate MS (+ve ion electrospray) m/z 450 (MH⁺).

Example 16 (R)-2-{4-[(4,6-Difluoro-1H-indol-2-yl)methyl]-amino}-piperidin-1-yl-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate



(a) Methyl 2,4-difluoro- α -azidocinnamate

To a solution of 2,4-difluorobenzaldehyde (1.0g) and ethyl azidoacetate (3.6g) in methanol (25ml) at -5 to -10 °C was added a 25% solution of sodium methoxide in methanol (6.0ml) over 10 min. The mixture was stirred for 2h at this temperature, then overnight at room temperature. Ether and ammonium chloride (sat. aqueous) were added and the phases were separated. The organic phase was washed with ammonium chloride, dried and evaporated to give the azidoester (1.43g).

(b) Methyl 4,6-difluoroindole-2-carboxylate.

The azidocinnamate (16a) (1.43g) was heated in toluene under reflux for 3h. The toluene was evaporated and the residue was chromatographed on silica (1:1 petrol/dichloromethane) to give the indole ester (0.16g).

MS (+ve ion electrospray) m/z 212 (MH⁺).

(c) 4,6-Difluoroindole-2-carboxaldehyde.

The ester (16b) (0.15g) in THF (2ml) was treated dropwise with lithium aluminium hydride (1M in THF, 0.71ml) at 0 °C. After 1.5h, additional lithium aluminium hydride (0.1ml) was added. After 0.5h the mixture was treated with 8% sodium hydroxide, ethyl acetate and sodium sulphate, filtered and evaporated. The resulting crude alcohol was dissolved in dichloromethane (3ml) and stirred with manganese (II) oxide for 6h. Filtration and evaporation of solvent gave the aldehyde (90mg).

MS (+ve ion electrospray) m/z 182 (MH⁺).

(d) Title compound


The aldehyde (16c) (30mg) and the amine (1d) (50mg) were stirred in 1:1 dichloromethane/methanol (4ml) over 3A molecular sieves at room temperature overnight. Sodium borohydride (10mg) was added and the mixture was stirred for 8h. The mixture was diluted with dichloromethane, water was added and the phases were separated. The organic phase was washed with water, dried and evaporated. Chromatography on silica (5-10% methanol/dichloromethane) gave the title compound as the free base (50mg).

¹H NMR (CDCl₃) δ : 1.52(m), 1.99(broad t), 2.20(t), 2.38(t), 2.45-2.65(m), 2.83(dd), 3.28(broad d), 3.92(s), 4.00(s), 5.43(dd), 6.38(s), 6.49(td), 6.87(d), 7.18(d), 7.38(dd), 7.65(d), 8.04(d), 8.77(d), 8.98(broad).

MS (+ve ion electrospray) m/z 467 (MH⁺).

A solution of the free base in chloroform was treated with 2 molar equivalents of oxalic acid (0.1 M solution in ether). The resulting precipitate was washed with ether and dried to give the dioxalate salt.

5 **Example 17 (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol, dioxalate**



(a) 7-Azaindole-2-carboxylic acid.

A solution of 7-azaindole (2.0g) in THF (30ml) was cooled to -70°C and n-butyl lithium (1.6M in hexanes, 11.1ml) was added dropwise. After 0.5h at -70°C , carbon dioxide was bubbled through for 10 min, followed by 10 min stirring. The mixture was allowed to warm to 0°C and the mixture was evaporated under vacuum to approximately half-volume. Fresh THF (15ml) was added, the mixture was cooled to -70°C and t-butyl lithium (1.7M in pentane, 10.5ml) was added dropwise. After stirring for 1h at -70°C , carbon dioxide was bubbled through for 10 min followed by stirring for 30 min. Water (1.2ml) was added and the mixture was allowed to warm to room temperature before pouring into saturated ammonium chloride. The aqueous solution was washed with ether, filtered and acidified to pH3.5. The white precipitate was collected and dried to give the acid (2.38g).

MS (+ve ion electrospray) m/z 163 (MH⁺).

(b) Methyl 7-azaindole-2-carboxylate.

The acid (17a) (1.0g) was partially dissolved in DMF (20ml) and methanol (2ml) and treated dropwise with trimethylsilyldiazomethane (2M in hexanes, 3.1ml). The mixture was stirred overnight then evaporated. Chromatography on silica (0-20-50-100% ethyl acetate/hexane) gave the ester (0.35g). MS (+ve ion electrospray) m/z 177 (MH⁺).

(c) 7-Azaindole-2-carboxaldehyde.

This was prepared (74%) from ester (17b) by the method of Example 16c. MS (+ve ion electrospray) m/z 147 (MH⁺).


(d) Title compound.

This was prepared from aldehyde(17c) and amine (1d) by the method of Example 16d Chromatography on silica (5% methanol/dichloromethane) gave the free base (35%). ¹H NMR (CDCl₃) δ : 1.51(m), 1.99(broad t), 2.18(t), 2.38(t), 2.50(m), 2.61(m), 2.80(dd), 3.25(broad d), 3.91(s), 4.07(s), 5.42(dd), 6.30(s), 7.05(dd), 7.16(d), 7.35(dd), 7.63(d), 7.84(d), 8.03(d), 8.28(d), 8.78(d), 10.03(broad).

MS (+ve ion electrospray) m/z 432 (MH⁺).

The free base was converted into the dioxalate salt by the method of Example 16.

Example 18 (R)-1-(6-Methoxy-[1,5]naphthyridin-4-yl)-2-{4-[(quinoxalin-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol, dimethanesulphonate



(a) Quinoxaline-2-carboxaldehyde.

This was prepared from methyl quinoxaline-2-carboxylate by the method of Example 16c, and used without purification.

This compound can also be prepared by oxidation of 2-methylquinoxaline with selenium dioxide, as described by Landquist et. al J. Chem. Soc. 2052 (1956).

(b) 4-Hydroxy-6-methoxy-[1,5]-naphthyridine

5-Amino-2-methoxypyridine (55g, 0.44mol) in methanol (1000ml) with methyl propiolate (40ml, 0.44mol) was stirred for 48 hours, then evaporated and the product purified by chromatography on silica gel (dichloromethane) followed by recrystallisation from dichloromethane-hexane (44.6g, 48%).

The unsaturated ester (10.5g, 0.05mol) in warm Dowtherm A (50ml) was added over 3 minutes to refluxing Dowtherm A, and after a further 20 minutes at reflux the mixture was cooled and poured into ether. The precipitate was filtered to give the title compound (6.26g, 70%).

(c) Bromomethyl-(6-methoxy-[1,5]-naphthyridin-4-yl)-ketone.

The naphthyridine (18b) (10g, 0.057mol) in dichloromethane (200ml) containing 2,6-lutidine (9.94ml, 0.086mol) and 4-dimethylaminopyridine (0.07g, 0.0057mol) was cooled in ice and treated with trifluoromethanesulfonic anhydride (10.5ml, 0.063mol). After stirring for 2.5 hours the mixture was washed with saturated ammonium chloride solution, dried, evaporated and purified on silica (dichloromethane). The triflate (13.2g, 0.044mol) in DMF (200ml) with triethylamine (12ml, 0.086mol) butyl vinyl ether (22ml, 0.17mol), palladium (II) acetate (0.97g, 0.0044mol) and 1,3-bis(diphenylphosphino)propane (1.77g, 0.0044mol) was heated at 60°C for 3 hours then evaporated and chromatographed on silica gel (dichloromethane) to give a yellow solid (10.7g, 95%). This was dissolved in THF (250ml), water (40ml) and treated with N-bromosuccinimide (7.4g, 0.042 mol) for 1 hour, then evaporated and chromatographed on silica gel (dichloromethane) to give the ketone (10.42g, 98%).

(d) (R)-2-Bromo-1-(6-methoxy-[1,5]-naphthyridin-4-yl)ethanol

The ketone (18c) (6.6g, 0.023mol) in toluene was treated with (+)-B-chlorodiisopinocampheylborane ((+)-DIP-chloride) (12g, 0.037mol) and stirred overnight, then diethanolamine (15g, 0.14mol) added and the mixture stirred for 3 hours, filtered and evaporated. Chromatography on silica gel (ethyl acetate-hexane) gave a
 5 white solid (4.73g, 73%).

(e) (R)-2-(6-Methoxy-[1,5]-naphthyridin-4-yl)oxirane

The alcohol (18d) (4.8g, 0.017mol) in methanol (20ml) was stirred with potassium carbonate (2.6g, 0.019 mol) for 1 hour, then evaporated and chromatographed on silica gel (ethyl acetate-hexane-dichloromethane) to give a solid (3.14g, 92%), (91% ee by
 10 chiral HPLC).

MS (+ve ion electrospray) m/z 203 (MH+).

(f) (R)-1-[2-Hydroxy-2-(6-methoxy-[1,5]naphthyridine-4-yl)]ethyl-4-amino piperidine

This was prepared from oxirane (18e) by the Method of Example (1c,d).

(g) Title Compound


This was prepared from the aldehyde (18a) and the amine (18f) by the method of Example 16d. Chromatography on silica (10% methanol/dichloromethane) gave the free base (54%).

¹H NMR (CDCl₃) δ: 1.61(m), 2.03(broad t), 2.22(t), 2.42(dd), 2.68(m), 2.86(broad d), 3.09(dd), 3.30(broad d), 4.03(s), 4.23(s), 5.73(dd), 7.11(d), 7.78(m), 8.09(m), 8.20(d),
 20 8.78(d), 8.91(s).

MS (+ve ion electrospray) m/z 445 (MH+).

The free base was dissolved in chloroform and treated with 2 molar equivalents of methanesulphonic acid (0.1M in ether) to give the dimethanesulphonate salt.

25 **Example 19 2-([1-[(R)-2-Hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-4-ylamino]-methyl)-quinolin-8-ol, dioxalate**




This was prepared from 8-hydroxyquinoline-2-carboxaldehyde and amine (1d) by the method of Example 16d. Chromatography on silica (10-20%
 30 methanol/dichloromethane) gave the free base (53%).

¹H NMR (CDCl₃) δ: 1.62(m), 2.02(broad t), 2.22(t), 2.41(t), 2.52(dd), 2.69(m), 2.83(dd), 3.28(broad d), 3.92(s), 4.16(s), 5.41(dd), 7.18(m), 7.31(m), 7.39(m), 7.48(d), 7.63(d), 8.03(d), 8.11(d), 8.77(d)

MS (+ve ion electrospray) m/z 459 (MH+).

35 The free base was converted into the dioxalate salt by the method of Example 20

Example 20. (R)-2-{4-[(Benzo[1,2,3]thiadiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol, dioxalate



5 (a) Benzo[1,2,3]thiadiazole-5-carboxaldehyde

This was prepared from methyl benzo[1,2,3]thiadiazole-5-carboxylate (0.291g) by the method of Example 16c, (except that the alcohol was stirred with manganese (II) oxide overnight) and used without purification.

(b) Title Compound


10 This was prepared from the aldehyde (20a) and the amine (1d) by the method of Example 16d. Chromatography on silica (10% methanol/dichloromethane) gave the free base as a foam.

¹H NMR (CDCl₃) δ: 1.60-1.90(m), 2.03(broad t), 2.25(t), 2.38 - 2.70(m), 2.86(broad d), 3.09(dd), 3.30(broad d), 3.95(s), 4.11(s), 5.47(dd), 7.18(d), 7.38(dd), 7.65(d), 7.75(d),
15 8.09(m), 8.05(m), 8.60(s), 8.78(d).

MS (+ve ion electrospray) m/z 450 (MH⁺)

The free base was converted into the dioxalate salt (45 mg) by the method of Example 16.

20 **Example 21 (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(quinoxalin-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol, dioxalate**



This was prepared from aldehyde (18a) by the method of Example 16d.


Chromatography on silica (10% methanol/dichloromethane) gave the free base (38%).

¹H NMR (CDCl₃) δ: 1.62(m), 2.05(broad t), 2.24(t), 2.43(t), 2.52(dd), 2.69(m), 2.85(dd),
25 3.30(broad d), 3.92(s), 4.22(s), 5.43(dd), 7.18(d), 7.37(dd), 7.65(d), 7.78(m), 8.03(d), 8.10(m), 8.78(d), 8.92(s).

MS (+ve ion electrospray) m/z 444 (MH⁺).

The free base was converted into the dioxalate salt by the method of Example 16.

30 **Example 22 (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(1-H-pyrrolo[3,2-b]pyridin-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol, dioxalate**



(a) 1H-Pyrrolo[3,2-b]pyridin-2-carboxaldehyde

This was prepared from methyl 1H-pyrrolo[3,2-b]pyridin-2-carboxylate (0.1g) and amine (1d) by the method of Example 16c, (except that the alcohol was stirred with manganese (II) oxide overnight) and used without purification.

(b) Title Compound


This was prepared from the aldehyde (22a) and the amine (1d) by the method of Example 16d. Chromatography on silica (10% methanol/dichloromethane) gave the free base as a foam.

¹H NMR (CDCl₃) δ: 1.50(m), 2.00(broad t), 2.19(t), 2.38(t), 2.42-2.68(m), 2.81(broad d), 3.36(broad d), 3.90(s), 4.09(s), 5.41(dd), 6.04(s), 7.06(m), 7.18(d), 7.38(dd), 7.60(m), 7.60(m), 8.09(m), 8.05(d), 8.41(m), 8.78(d), 9.15(s).

MS (+ve ion electrospray) m/z 432 (MH⁺)

The free base was converted into the dioxalate salt (69mg) by the method of Example 16.

Example 23 2-((1-((R)-2-Hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl)-piperidin-4-ylamino)-methyl)-quinolin-8-ol, dimethanesulphonate




This was prepared from 8-hydroxyquinoline-2-carboxaldehyde and the amine (18f) by the method of Example 16d. Chromatography on silica gel gave the free base.

¹H NMR (CDCl₃) δ: 1.49-1.73(m), 1.92-2.10(m), 2.1-2.25(m), 2.31-2.48(m), 2.60-2.74(m), 2.69(m), 2.78-2.81(m), 3.09(dd), 3.25-3.38(m), 4.02(s), 4.16(s), 5.73(dd), 7.05-7.22(m), 7.26-7.34(m), 7.36-7.48(m), 7.79(d), 8.09(d), 8.20(d), 8.77(d)

MS (+ve ion electrospray) m/z 460 (MH⁺).

The free base was converted into the dimethanesulphonate salt as for Example 18.

Example 24 (R)-2-((1-((4-Fluoro-1H-benzimidazol-2-ylmethyl)-amino)-piperidin-1-yl)-1-(6-methoxyquinolin-4-yl)-ethanol, dioxalate



(a) 3-Fluoro-benzene-1,2-diamine

A solution of 2-fluoro-6-nitro-phenylamine [K.L. Kirk and L.A. Cohen *J. Org. Chem.* 34, 384-389 (1969)] (1.05g) in ethanol (50ml) was hydrogenated over 10% palladium on carbon (0.5g), filtered and evaporated to give a brown solid, used without purification.

MS (+ve ion electrospray) m/z 127 (MH⁺).

(b) (4-Fluoro-1H-benzimidazol-2-yl)-methylamine

A mixture of glycine (7.0g) and 3-fluoro-benzene-1,2-diamine (28a) in 5M hydrochloric acid (5mL) was heated under reflux for 20 hours and evaporated. Sodium carbonate solution was added to pH 10 and the solution was extracted with dichloromethane. The aqueous fraction was evaporated to dryness and the residue was extracted with 10% methanol in chloroform, dried and evaporated to give a foam (0.53g). MS (+ve ion electrospray) m/z 166 (MH⁺).

(c) Title compound


This was prepared from the amine (24b) (93.5mg) and recrystallised ketone (7b) (0.17g), by the method of Example (7c). Purification on silica gel (2-15% methanol-dichloromethane) afforded the title compound as an oil (0.102g).

MS (+ve ion electrospray) m/z 450 (MH⁺).

¹H NMR (CDCl₃) δ: 1.50 (2H, m), 2.00 (2H, broad t), 2.10-2.60 (4H, m), 2.80 (2H, broad dd), 3.25 (1H, broad d), 3.90 (3H, s), 4.20 (2H, s), 5.41 (1H, dd), 6.95 (1H, m), 7.15 (2H, m), 7.35 (2H, m), 7.62 (1H, d), 8.05 (1H, d), 8.80 (1H, d)

This was converted to the dioxalate salt (0.13g) by the method of Example 16.

Example 25 (R)-2-{4-[(Benzothiazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol, dioxalate



(a) 2-Chloromethyl-benzothiazole

This was prepared from 2-amino-benzenethiol by the method of B.C. Mylari et al [Syn. Commun. 19, 2921-4 (1989)]

(b) Title compound

A solution of the amine (1d) 0.2g) and 2-chloromethylbenzothiazole (25a) (0.122g) in dry DMF (3ml) containing diisopropylethylamine (0.2ml) and potassium iodide (4 crystals) was stirred at room temperature for 18h and evaporated to dryness. Sodium bicarbonate solution was added and the mixture was extracted with


dichloromethane, washed with water and dried over sodium sulfate. The product was chromatographed on silica gel (2-5% methanol-dichloromethane) to afford a foam (0.066g).

MS (+ve ion electrospray) m/z 449 (MH⁺).

- 5 ¹H NMR (CDCl₃) δ : 1.55 (2H, m), 2.05 (2H, broad t), 2.15 - 2.75 (4H, m), 2.85 (2H, broad dd), 3.30 (1H, broad d), 3.91 (3H, s), 4.29 (2H, s), 5.48 (1H, dd), 7.19 (1H, d), 7.40 (3H, m), 7.65 (1H, d), 7.90 (1H, d), 8.00 (1H, d), 8.04 (1H, d), 8.78 (1H, d)

This was converted to the dioxalate salt (0.09g) by the method of Example 16.

- 10 **Example 26 (R)-2-(4-[(R)-1-(2,3-Dihydro-[1,4]dioxino[2,3-pyridin-3-yl)methyl]-amino]-piperidin-1-yl)-1-(8-fluoro-6-methoxy-quinolin-4-yl)-ethanol, dioxalate**



- (a) 8-Fluoro-6-methoxy-quinolin-4-ol

- 2-Fluoro-4-methoxy-phenylamine (3.80g, 26.7mmol) and methyl propiolate
15 (2.37ml, 0.267mol) in methanol (100ml) was stirred for 72 hours at room temperature, then heated at 50°C for 24 hours. It was evaporated and the product purified by chromatography on silica gel (dichloromethane) to give a solid (1.66g), a portion of which was recrystallised from dichloromethane-hexane.

- The unsaturated ester (0.96g) in warm Dowtherm A (5ml) was added over 3 minutes to
20 refluxing Dowtherm A (15ml), and after a further 20 minutes at reflux the mixture was cooled and poured into ether. The precipitate was filtered to give the title compound (0.50g, 61%).

- (b) 1,1,1-Trifluoro-methanesulfonic acid 8-fluoro-6-methoxy-quinolin-4-yl ester

- The quinolinol (26a) (0.48g) and dimethylaminopyridine (0.03g) in
25 dichloromethane (20ml) and 2,6-lutidine (0.48ml) was treated dropwise with triflic anhydride (0.48ml) and the mixture was stirred at room temperature for 4 hours. It was washed with saturated ammonium chloride, dried, evaporated, and chromatographed on silica gel (dichloromethane) to afford a yellow solid (0.69g).

MS (+ve ion electrospray) m/z 326 (MH⁺).

- 30 (c) 2-Bromo-1-(8-fluoro-6-methoxy-quinolin-4-yl)-ethanone

The triflate (26b) (19.1g) was converted to the bromomethyl ketone (8.6g) by the method of Example (18c).

MS (+ve ion electrospray) m/z 298/300 (MH⁺).

(d) 8-Fluoro-6-methoxy-4-(R)-oxiranyl-quinoline

The bromomethyl ketone (26c) (8.6g) was converted to the oxirane (1.04g) by the methods of Examples (18d,e).

MS (+ve ion electrospray) m/z 220 (MH⁺).

5 (e) 1-[(R)-2-(8-Fluoro-6-methoxy-quinolin-4-yl)-2-hydroxy-ethyl]-piperidin-4-one

This was prepared from oxirane (26d) (1.04g) by the Method of Example (7a,b) to give the ketone (1.1g) as a foam.

MS (+ve ion electrospray) m/z 319 (MH⁺).

(e) Title compound

10 This was prepared from ketone (26e) (0.10g) and C-[(R)-1-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)]-methylamine [C. Comoy *et al. Med. Chem. Res.* 6, 392-399 (1996)] (0.055g) by the method of Example (7c). Purification on silica gel (2-10% methanol-dichloromethane) afforded the title compound as a foam (0.093g).


MS (+ve ion electrospray) m/z 469 (MH⁺).

15 ¹H NMR (CDCl₃) δ : 1.50 (2H, m), 1.95 (2H, broad t), 2.20-2.60 (4H, m), 2.80 (2H, broad dd), 2.95 (2H, m), 3.25 (1H, broad d), 3.90 (3H, s), 4.10 (1H, m), 4.28 (1H, dd), 4.45 (1H, m), 5.40 (1H, dd), 6.88 (1H, m), 7.00 (1H, s), 7.12 (1H, dd), 7.25 (1H, dd), 7.70 (1H, d), 7.82 (1H, m), 8.80 (1H, d)

This was converted to the dioxalate salt (0.131g) by the method of Example 16.

20

Example 27 1-{4-[(8-Hydroxy-quinolin-2-ylmethyl)-amino]-piperidin-1-yl}-2-(6-methoxy-quinolin-4-yl)-ethanone, oxalate



(a) (6-Methoxy-quinolin-4-yl)-acetic acid ethyl ester

25 6-Methoxy-4-methyl-quinoline (0.791g, 4.572mmol) was dissolved in anhydrous diethyl ether and cooled to 0°C under an argon atmosphere. To the stirred mixture was added sodamide as a 50% w/w slurry in toluene (0.36g, 4.57mmol). The resulting slurry was allowed to warm to room temperature and was stirred for 1 hour. To this was added diethylcarbonate (0.28ml, 2.29mmol). The reaction mixture was then stirred at reflux for 30 10 hours after which time it was quenched with water (2ml). The mixture was partitioned between ethyl acetate (2x100ml) and water (20ml). The organic phases were combined and dried over magnesium sulfate. The volatiles were removed under reduced pressure

and the residue subjected to purification on silica gel using an ethyl acetate-hexane gradient. This provided the desired product as a brown oil (90mg, 7%).

MS (APCI+) m/z 246 (MH+).

(b) {1-[2-(6-Methoxy-quinolin-4-yl)-ethanoyl]-piperidin-4-yl}-carbamic acid *tert*-butyl ester

The ester (27a) (90mg, 0.367mmol) was dissolved in a mixture of tetrahydrofuran and water (3:1, 3ml) and sodium hydroxide (44mg, 1.10mmol) was added. The solution was stirred at room temperature for 10 hours and then the solvent was removed under reduced pressure. The residue was re-dissolved in aqueous hydrochloric acid (1N, 5ml) and then the solvent removed *in vacuo*. The residue obtained was dissolved in *N,N'*-dimethylformamide (3ml) and to this was added O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (139mg, 0.367mmol), piperidin-4-yl-carbamic acid *tert*-butyl ester (80mg, 0.404mmol) and diisopropylethylamine (0.19ml, 1.10mmol). The resulting solution was stirred at room temperature for 10 hours. The solvent was then removed under vacuum and the residue partitioned between ethyl acetate (2x100ml) and water (20ml). The organic phases were combined and dried over magnesium sulfate then concentrated under reduced pressure. The resultant oil was purified on silica gel using an ethyl acetate-hexane gradient. This provided the desired compound as a white solid (139mg, 95%).

MS (APCI+) m/z 400 (MH+).

(c) Title compound


The amide (27b) (177mg, 0.444mmol) was dissolved in dichloromethane (2ml) and trifluoroacetic acid (1ml) was added. The resulting solution was stirred at room temperature for 2 hours after which time the volatiles were removed under reduced pressure. The residue was dissolved in dichloromethane and methanol (3:1, 3ml) and 4Å molecular sieves were added (1g). To the solution 8-hydroxy-quinoline-2-carboxaldehyde (77mg, 0.444mmol) was added and allowed to stir at room temperature under argon for 10 hours. Sodium borohydride (34mg, 0.888mmol) was then added to the reaction mixture and stirred for a further 3 hours at room temperature. The mixture was quenched by the addition of water (2ml). The volatiles were removed *in vacuo* and the residue partitioned between ethyl acetate (2x100ml) and water (20ml). The organic phases were combined and dried over magnesium sulfate. The solvent was removed under reduced pressure and the residue purified on silica gel using a dichloromethane-methanol gradient. This provided the desired compound as a colourless oil (17mg, 8%).

^1H NMR (CDCl_3) δ : 1.40-1.60 (4H, m), 1.85-2.00 (2H, m), 2.75-3.00 (2H, m), 3.16 (1H, m), 3.81 (1H, m), 3.97 (3H, s), 4.13 (2H, s), 4.17 (2H, s), 4.45 (1H, m), 7.19 (1H, dd), 7.30 (2H, m), 7.34 (1H, d), 7.52 (2H, m), 7.56 (1H, dd), 8.13 (1H, d), 8.91-8.95 (2H, m).

MS (APCI+) m/z 457 (MH+).

The oxalate salt was generated in a manner similar to Example 1.

Example 100 (R)-2-{4-[(Benzothiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol, dioxalate



(a) Benzothiazole-5-carboxylic acid

4-Chloro-3-nitro-benzoic acid (22g) was suspended in water (750ml) containing sodium hydroxide (4.33g) and sodium sulfide hydrate (32g) was added and the mixture was heated under reflux for 24 hours. It was neutralised with 5M hydrochloric acid and extracted with ethyl acetate to afford a foam (13.5g), which was heated under reflux in formic acid (300ml) containing zinc dust (1.5g) for 6 hours. The reaction mixture was cooled, filtered and evaporated and the residue was diluted with water, adjusted to pH 6.5 and evaporated to dryness. It was chromatographed on silica gel (methanol-dichloromethane then methanol-ethyl acetate) to give the product (10.4g).

MS (-ve ion electrospray) m/z 178 (M-H).

(b) Benzothiazol-5-yl-methanol

The acid (100a) (0.53g) in tetrahydrofuran (20ml) and triethylamine (0.49ml) was cooled to 0°C and isobutylchloroformate (0.42ml) was added dropwise and the solution was stirred at 0°C for 1 hour, when it was filtered into a stirred solution of sodium borohydride (0.24 g) in ice/water (50 ml). The mixture was stirred at 0°C for 0.5 hour, neutralised with 2M hydrochloric acid, evaporated to half volume, and extracted with dichloromethane. The organic fraction was dried, evaporated to dryness and chromatographed on silica gel (ethyl acetate) to give the alcohol (0.345g).

MS (+ve ion electrospray) m/z 166 (MH)⁺

(c) Benzothiazole-5-carboxaldehyde

A stirred solution of the alcohol (100b) (0.61g) in dichloromethane (25ml) was treated with manganese dioxide (3.6g) for 18 hours and was filtered and evaporated to give a solid (0.505g).

MS (+ve ion electrospray) m/z 164 (MH)⁺

(d) Title compound

A solution of theamine (1d; 94% ee) (0.70g) and carboxaldehyde (100c) (0.505 g) in dichloromethane (15ml) and methanol (15ml) was treated with 3A molecular sieves and the mixture was stirred at room temperature for 18 hours. The mixture was treated with sodium borohydride (140 mg) in portions and after 18 hours the solution was diluted

with water, extracted with dichloromethane and chromatographed on silica gel (methanol-dichloromethane) to afford the free base of the title compound as an oil (0.559g).

- δ H (CDCl₃): 1.50-2.10 (6H, m), 2.20-2.70 (2H, m), 2.85 (2H, m), 3.30 (1H, m), 3.90 (3H, s), 4.05 (2H, s), 5.45 (1H, dd), 7.20 (1H, d), 7.35 (1H, dd), 7.48 (1H, d), 7.62 (1H, d), 7.90 (1H, d), 8.05 (1H, d), 8.10 (1H, s), 8.75 (1H, d), 9.0 (1H, s).
- MS (+ve ion electrospray) m/z 449 (MH⁺).


The dioxalate salt was prepared by the same method as for Example 1.

The following Examples were prepared by analogous methods.

10 A: by method of Example 16

B: by method of Example 7

C: by method of Example 25

Example	Method of synthesis	salt			
		AY dioxalate	DZ dimesylate	R trihydrochloride	
50	A	AY			4,7-difluoro-1H-indol-2-yl
51	A	AY			7-nitro-1H-indol-2-yl
52	A	AY			4-fluoro-1H-indol-2-yl
53	A	AY			1H-pyrrolo[2,3-b]pyridin-2-yl
54	A	AY			4-chloro-1H-indol-2-yl
55	A	AY			2-chloro-quinolin-3-yl
56	A	AY			3-methyl-benzofuran-2-yl
57	A	AY			5-fluoro-1H-indol-2-yl
58	A	AY			isoquinolin-3-yl
59	B	AY			2,3-dihydrobenzo[1,4]dioxin-2-yl
60	A	AY			benzo[b]thiophen-2-yl
61	A	AY			5-methylbenzothiophen-2-yl
62	A	AY			5,7-difluoro-1H-indol-2-yl
63	C	AY			benzoxazol-2-yl
64	A	AY			6-chloro-1H-indol-2-yl
65	C	DZ			7-fluoro-3-methyl-3H-quinazolin-4-one-2-yl
66	A	AY			6-cyano-1H-indol-2-yl
67	C	AY			4,5-difluorobenzoxazol-2-yl
68	A	AY			5-nitro-1H-indol-2-yl
69	C	DZ			imidazo[1,2-a]pyridin-2-yl
70	A	AY			3,6-dichloro-1H-indol-2-yl


71	A	AY	1H-indol-6-yl
72	A	AY	5-chloro-1H-indol-2-yl
73	C	AY	3H-quinazolin-4-one-2-yl
74	C	DZ	6,7-difluoro-3H-quinazolin-4-one-2-yl
75	A	AY	7-methoxybenzofuran-2-yl
76	C	AY	5-fluoro-benzoxazol-2-yl
77	A	AY	5-methoxy-benzofuran-2-yl
78	C	DZ	5-fluoro-3H-quinazolin-4-one-2-yl
79	A	DZ	benzo[1,2,5]-oxadiazol-5-yl
80	A	AY	5-trifluoromethoxy-1H-indol-2-yl
81	C	AY	6-fluoro-benzoxazol-2-yl
82	C	AY	oxazolo[4,5-b]-pyridin-2-yl
83	B	DZ	3H-imidazo[4,5-b]-pyridin-2-yl
84	C	AY	6-fluoro-imidazo[1,2-a]pyridin-2-yl
85	a	R	2-hydroxyquinolin-3-yl
86	A	AY	4-benzyloxy-1H-indol-2-yl
87	b	DZ	4-hydroxy-1H-indol-2-yl
88	A	AY	7-methanesulphonyl-1H-indol-2-yl
89	C	AY	imidazo-[1,2-a]-pyrimidin-2-yl
90	A	AY	2-methyl[1,8]-naphthyridine-3-yl
91	A	AY	5-benzyloxy-1H-indol-2-yl
92	A	AY	3-fluoro-1H-indol-2-yl
93	A	AY	benzo[1,2,5]thiadiazol-5-yl
94	B	DZ	3-(R)-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl
95	A	AY	8-hydroxyquinoxalin-2-yl
96	A	AY	cinnolin-3-yl
97	A	AY	6-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl
98	A	AY	5-hydroxyquinoxalin-2-yl
99	A	AY	pyrazolo[1,5-a]pyridin-2-yl
101	A	AY	3-fluoropyrazolo[1,5-a]pyridin-2-yl
102	A	R	8-hydroxy-2H-isoquinolin-1-one-3-yl
103	C	DZ	pyrido[1,2-a]pyrimidin-4-one-2-yl
104	A	AY	6-fluoropyrazolo[1,5-a]pyridin-2-yl
105	B	AY	4-nitro-1H-benzimidazol-2-yl
106	B	AY	4-fluoro-1H-benzimidazol-2-yl
107	A	AY	5-trifluoromethyl-thieno[3,2-b]pyridin-6-yl
108	C	DZ	7-fluoro-3-methyl-3H-quinazolin-4-one-2-yl
109	A	AY	imidazo[1,2-b]pyridazin-2-yl
110	C	AY	quinazolin-2-yl
111	A	AY	quinoxalin-6-yl

112	C	AY	7-fluoro-quinazolin-2-yl
113	B	AY	3-(R,S)-3,4-dihydro-2H-benzo[1,4]thiazin-3-yl
114	A	AY	7-benzyloxy-1H-indol-2-yl
115	A	AY	benzo[1,2,3]thiadiazol-6-yl
116	C	DZ	thiazolo[3,2-a]pyrimidin-5-one-7-yl
117	B	AY	thiazolo[5,4-b]pyridin-2-yl
118	A	AY	pyrido[1,2-a]pyrimidin-4-one-3-yl
119	A	AY	1-isopropyl-1H-benzotriazol-5-yl
120	B	AY	4-cyano-1H-benzimidazol-2-yl
121	C	AY	6-chloro-imidazo[1,2-b]pyridazine-2-yl
122	A	AY	3H-benzothiazol-2-one-5-yl
123	B	DZ	3-(S)-(2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl
124	A	AY	5-chloro-3H-benzooxazol-2-one-6-yl

^a Prepared from Example 55 by heating in 5M HCl/dioxan (1:1) under reflux for 18 hours

^b Prepared from Example 86 by hydrogenation over palladium/carbon

Example 150. 4-[(4,7-Difluoro-1-H-indol-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (8-fluoro-6-methoxy-quinolin-4-yl)-amide, oxalate



5 (a) 8-Fluoro-6-methoxy-quinolin-4-ylamine

A solution of the triflate (26b) (0.69g) in pyridine (10ml) was treated with n-propylamine hydrochloride (1.2g) and the mixture heated at reflux for 16 hours. The reaction mixture was evaporated, dissolved in 0.05M HCl, washed with dichloromethane, basified with sodium hydroxide solution and re-extracted with dichloromethane. The combined organics were dried (Na₂SO₄), evaporated, and chromatographed on silica gel (2-5% methanol in dichloromethane) to afford an orange solid (1.0g).
 10 MS (+ve ion electrospray) m/z: 193 (MH⁺).

(b) 4-(1-Imidazolylcarbonyl)amino-8-fluoro-6-methoxyquinoline

A suspension of the amine (150a) (0.213g) in ethanol-free chloroform (5 ml) was treated with 4-N,N-dimethylaminopyridine (0.153g) and 1,1'-carbonyl diimidazole (0.246g) for 5.5 hours and the reaction mixture was filtered, evaporated to dryness, and used without purification.
 15

(c) [1-(8-Fluoro-6-methoxy-quinolin-4-ylcarbonyl)-piperidin-4-yl]-carbamic acid *tert*-butyl ester

To a stirred solution of the imidazolylcarbonyl compound (150b) in anhydrous DMF (3ml) was added 4-*tert*-butoxycarbonylaminopiperidine hydrochloride (0.26g) and
 20

potassium carbonate (0.15g). The mixture was heated at 70°C for 12 hours, then cooled, filtered and evaporated. The residue was dissolved in ethyl acetate, washed with water, dried and evaporated. The crude product was chromatographed on silica gel eluted with 2-4% methanol/ dichloromethane to give a gum (0.465g).

5 MS (+ve ion electrospray) m/z 419 (MH+)

(d) 4-Amino-piperidine-1-carboxylic acid (8-fluoro-6-methoxy-quinolin-4-yl)-amide

The *tert*-butoxycarbonylamino compound (150c) (0.465g) was dissolved in dichloromethane (4ml), cooled in ice, and treated with trifluoroacetic acid (3ml). The solution was stirred at room temperature for 2 hours, then evaporated *in vacuo*. The

10 residue was basified with sodium bicarbonate solution and evaporated. It was extracted with 10% methanol/dichloromethane, dried and evaporated to give a foam.

MS (+ve ion electrospray) m/z 317 (MH+)

(e) Ethyl 4,7-difluoroindole-2-carboxylate.

A mixture of 2,5-difluorophenylhydrazine (4.0g), ethyl pyruvate (3.1ml) and
15 glacial acetic acid (40ml) was heated under reflux for 1.5h. The mixture was evaporated, then toluene was added and re-evaporated. The crude product (6.7g) was heated under reflux with anhydrous p-toluenesulphonic acid (19.1g) for 5.5h.

The cooled mixture was dissolved in ethyl acetate, washed with sodium bicarbonate and brine, dried and evaporated. Chromatography on silica gel (1:1 dichloromethane/petrol)
20 followed by recrystallization (dichloromethane/hexane) gave the indole ester (0.75g).

(f) 4,7- Difluoroindole-2-carboxaldehyde.

This was prepared (55%) from the ester (150e) by the method of Example (16c).

MS (+ve ion electrospray) m/z 182 (MH+).

(g) Title compound

25 A mixture of amine (150d) (0.10g) and 4,7-difluoro-1H-indole-2-carboxaldehyde (150f) (0.06g) and 3A molecular sieves in dichloromethane (4ml) and methanol (4ml) was stirred at room temperature for 6 hours, sodium borohydride was added and the mixture was stirred for a further 24 hours. It was quenched with water and the organic layer separated, dried, evaporated and chromatographed on silica gel (2%
30 methanol/dichloromethane) to afford a solid (0.042g).

MS (+ve ion electrospray) m/z 484 (MH+)

This was converted to the oxalate salt by the method of Example 16.

The Examples 151 and 152 were prepared by analogous methods to Example 150

Example	salt	
	G oxalate	 R
151	G	8-hydroxyquinoxalin-2-yl
152	G	8-hydroxyquinolin-2-yl


The Examples 170 and 171 were prepared by analogous methods to Example 26

Example	salt	
	AY di-oxalate	 R
170	AY	4-fluoro-1H-benzimidazol-2-yl
171	AY	3H-imidazo[4,5-b]pyridin-2-yl

- 5 Examples 180 and 181 were prepared from 6-trifluoromethoxy-quinolin-4-ylamine by the method of Example 150

Example	salt	
	G oxalate	 R
180	G	8-hydroxyquinoxalin-2-yl
181	G	5-hydroxyquinoxalin-2-yl

- 10 **Example 300 (R)-2-{4-[(4,6-Difluoro-1H-benzimidazol-2-yl)methyl]-amino}-piperidin-1-yl-1-(6-methoxy[1,5]naphthyridin-4-yl)-ethanol, dioxalate**



(a) 1-[(R)-2-Hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-piperidin-4-one

This was prepared from the oxirane (18e) by the method of Example (7a and b), and had an enantiomeric excess of 90%.

MS (+ve ion electrospray) m/z 302 (MH⁺)

(b) Title compound

- 5 This was prepared from ketone (300a) and amine (12a) by the method of Example (7c)


MS (+ve ion electrospray) m/z 469 (MH⁺)

This was converted to the oxalate salt by the method of Example 16


- 10 The following Examples were prepared by analogous methods.

D: by method of Example 18

E: by method of Example 300

Example	Method of synthesis	salt AY dioxalate DZ dimesylate	
301	D	DZ	4,7-difluoro-1H-indol-2-yl
302	D	AY	1H-indol-2-yl
303	D	DZ	4,6-difluoro-1H-indol-2-yl
304	D	AY	isoquinolin-3-yl
305	E	AY	benzoxazol-2-yl
306	D	AY	1H-pyrrolo[2,3-b]pyridin-2-yl
307	E	AY	imidazo[1,2-a]pyridin-2-yl
308	E	AY	4-fluoro-1H-benzimidazol-2-yl
309	E	DZ	3-(R)-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl
310	E	DZ	3-(S)-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl
311	D	AY	benzo[1,2,3]thiadiazol-5-yl
312	D	AY	imidazo[1,2-a]pyridazin-2-yl
313	D	AY	3-fluoropyrazolo[1,5-a]pyridin-2-yl

- 15 **Example 400.** 4-[(4,7-Difluoro-1H-indol-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide, oxalate



(a) 4-Amino-6-methoxy-[1,5]naphthyridine

A solution of 1,1,1-trifluoro-methanesulfonic acid 6-methoxy-[1,5]naphthyridin-4-yl carboxylic acid ester (8.0g) [prepared as described in Example (18c)] and propylamine hydrochloride (15.8 g) in pyridine (120 ml) was heated at reflux for 4 hours.

- 5 The solvent was evaporated and the mixture dissolved in 0.05M hydrochloric acid (600 ml) and washed with dichloromethane. The mixture was basified with 40% sodium hydroxide and extracted with dichloromethane. The extracts were dried, evaporated and chromatographed on silica gel (2-5% methanol in dichloromethane) to give an orange solid (3.6 g, 63%).

- 10 ¹H NMR (CDCl₃) δ: 4.05 (3H, s), 5.25 (2H, brs), 6.71 (1H, d, J=5Hz), 7.08 (1H, d, J=9Hz), 8.09 (1H, d, J=9Hz), 8.39 (1H, d, J=5Hz).

MS (+ve ion electrospray) m/z: 176 (MH⁺).

(b) 4-*tert*-Butoxycarbonylamino-1-(6-methoxy-[1,5]naphthyridin-4-yl)aminocarbonylpiperidine

- 15 To a solution of 4-amino-6-methoxy-[1,5]naphthyridine (Example 400a) (2.1g, 13.5 mmol) and 4-(dimethylamino)pyridine (1.62g) in anhydrous chloroform (45ml) was added N,N'-carbonyldiimidazole (3.28g, 20.1 mmol). The mixture was stirred for 4h at room temperature, then evaporated and the residue was dissolved in anhydrous DMF (45ml). 4-*tert*-Butoxycarbonylamino-piperidine hydrochloride (3.34g, 13.5 mmol) and potassium carbonate (1.89g) were added, and the mixture was heated at 70°C overnight. The mixture was evaporated and the residue was mixed with water (120ml). The solid was filtered off and dried (3.89g).

MS (+ve ion electrospray) m/z 402 (MH⁺).

(c) 4-Amino-1-(6-methoxy-[1,5]naphthyridin-4-yl)aminocarbonylpiperidine

- 25 The *tert*-butoxycarbonylamino compound (400 b) (3.88g, 9.7 mmol) was treated with trifluoroacetic acid and hydrogen chloride (4M in dioxan) as described in Example (1d). The crude hydrochloride was dissolved in water and washed twice with dichloromethane, basified to pH9 and evaporated to dryness. Extraction with 10% methanol/ dichloromethane gave the free base (3.45g).

- 30 MS (+ve ion electrospray) m/z 302 (MH⁺).

(d) Title compound

- A mixture of amine (400c) (0.10g) and 4,7-difluoro-1H-indole-2-carboxaldehyde (150f) (0.06g) and 3A molecular sieves in dichloromethane (4ml) and methanol (4ml) was stirred at room temperature for 6 hours, sodium borohydride (0.020g) was added and the mixture was stirred for a further 24 hours. It was quenched with water and the organic layer separated, dried, evaporated and chromatographed on silica gel (2% methanol/dichloromethane) to afford a solid (0.062g).

MS (+ve ion electrospray) m/z 467 (MH⁺)

¹H NMR (CDCl₃) δ: 1.45 (2H, m), 1.75 (2H broad s), 2.05 (2H, broad d), 2.82 (1H, m), 3.12 (2H, t), 4.02 (3H, s), 4.05 (2H, s), 4.18 (2H, broad d), 6.45 (1H, broad s), 6.70 (2H, m), 7.12 (1H, d), 8.24 (1H, d), 8.30 (1H, d), 8.68 (1H, d), 9.08 (2H, broad s).

- 5 This was converted to the oxalate salt by the method of Example 16.


The following Examples were prepared by analogous methods

A by method of Example 400


B by method of Example (406a) and then Example 400

- 10 C by method of Example 403

D by method of Example (400a-c) and then Example 25

Example	Method of synthesis	salt G oxalate S mesylate	X	
401	A	G	N	1H-indol-2-yl
402	A	S	N	quinoxalin-2-yl
404	A	G	N	1H-pyrrolo[2,3-b]pyridin-2-yl
405	A	G	N	isoquinolin-3-yl
407	B	G	CH	3-(R)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl
408	C	G	N	4-fluoro-1H-benzimidazol-2-yl
409	A	G	N	8-hydroxyquinolin-2-yl
410	D	G	N	benzothiazol-2-yl
411	A	G	N	8-hydroxyquinoxalin-2-yl
412	A	G	N	cinnolin-3-yl
413	A	G	N	benzo[1,2,5]thiadiazol-5-yl
414	A	G	N	5-hydroxyquinoxalin-2-yl

- 15 **Example 403 4-[(4,6-Difluoro-1H-benzimidazol-2-yl)methyl]-amino]-piperidine-1-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide, oxalate**



(a) 4-Oxo-1-(6-methoxy-[1,5]naphthyridin-4-yl)aminocarbonylpiperidine, ethylene ketal

- A solution of 4-amino-6-methoxy-[1,5]naphthyridine (400a) (0.32g, 2 mmol) in chloroform (6 ml) was treated with N,N-dimethylaminopyridine (0.24g, 2 mmol) then
 5 1,1'-carbonyldiimidazole (0.42g, 2.6 mmol). After 2 hours the chloroform was removed by evaporation and the residue treated with a solution of 4-oxopiperidine, ethylene ketal (0.31g, 0.22mmol) in N,N-dimethylformamide (5 ml). The mixture was heated at 100°C for 1 hour, then partitioned between ethyl acetate and dilute brine. The organic extract was washed with water (3x), brine, dried and evaporated to give a yellow solid (0.8g).
 10 Chromatography on silica gave the product as a white solid (0.47g, 71%).
 MS (+ve ion electrospray) m/z 345 (MH+).

(b) 4-Oxo-1-(6-methoxy-[1,5]naphthyridin-4-yl)aminocarbonylpiperidine

- A solution of Example (403a) (0.46g, 1.4 mmol) in acetone (25 ml) and water (5 ml) was treated with concentrated hydrochloric acid (0.2 ml) and the mixture heated to
 15 reflux for 4 hours. The cooled mixture was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic extract was dried and evaporated to give a white solid (0.4g). Chromatography gave the title compound (0.2g, 46%).
 MS (+ve ion electrospray) m/z 301 (MH+).


20 (c) Title compound

This was prepared from ketone (403b)(0.08g) and (4,6-difluoro-1H-benzimidazol-2-yl)-methylamine (12a) (0.049g) by the method of Example (7c) to give a solid (0.046g).

MS (+ve ion electrospray) m/z 468 (MH+).

25 This was converted to the oxalate salt by the method of Example 16.

Example 406. 4-[(1H-Indol-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (6-methoxy-quinolin-4-yl)-amide, oxalate



30

(a) 4-Amino-6-methoxyquinoline

Curtius rearrangement of 6-methoxyquinoline-4-carboxylic acid (1a)(4g, 20mmol) with diphenylphosphoryl azide (4.3ml, 20mmol) and triethylamine(3.5ml) in *tert*-butanol (25ml) at 85°C gave, after chromatography (silica gel, ethyl acetate-dichloromethane) the

N-*tert*-butoxycarbamate (2.47g). Treatment with aqueous hydrochloric acid at reflux, followed by basification and extraction with ethyl acetate gave 4-amino-6-methoxyquinoline (0.74g).

- This compound may also be prepared from 4-hydroxy-6-methoxyquinoline by chlorination with phosphorus oxychloride, to give the 4-chloroquinoline, followed by treatment with *n*-propylamine hydrochloride by the method of Example (400a).

(b) 4-(1-Imidazolylcarbonyl)amino-6-methoxyquinoline

- A suspension of 4-amino-6-methoxyquinoline (406a) (2.0g, 11 mmol) in ethanol-free chloroform (60 ml) was treated with 4-*N,N*-dimethylaminopyridine (1.4g, 11.4 mmol) and 1,1'-carbonyl diimidazole (2.6g, 15.9 mmol). The suspension became clear over 1 hour then precipitation occurred. After a further 2 hours, filtration afforded the product as a white solid which was dried *in vacuo* (1.8g, 59%).

(c) 4-*tert*-Butoxycarbonylamino-1-(6-methoxyquinolin-4-yl)aminocarbonylpiperidine.

- The imidazolylcarbonyl compound (406b) (0.268g, 1 mmol), 4-*tert*-butoxycarbonylamino-piperidine hydrochloride (0.24g, 1 mmol) and potassium carbonate (0.14g) were heated in DMF (2ml) at 70 °C for 12h. The mixture was evaporated and the residue was dissolved in ethyl acetate, washed with water and brine, dried and evaporated. The crude product was chromatographed on silica gel eluted with 0-4% methanol/dichloromethane to give the pure product (0.28g).

- MS (+ve ion electrospray) *m/z* 401 (MH⁺).

(d) 4-Amino-1-(6-methoxyquinolin-4-yl)aminocarbonylpiperidine


- The *tert*-butoxycarbonylamino compound (406c)(0.275g, 0.69 mmol) was treated with trifluoroacetic acid and hydrogen chloride as in Example (1d). The crude hydrochloride was dissolved in water, basified (pH 8-9) and evaporated, and the residue was extracted with 10% methanol/dichloromethane to give the free base (0.23g). MS (+ve ion electrospray) *m/z* 301 (MH⁺).

(e) Title compound

- This was prepared from amine (406d)(0.065g) and 1H-indole-2-carboxaldehyde (0.032g) by the method of Example (400d) to afford the free base (0.028g). MS (+ve ion electrospray) *m/z* 430 (MH⁺).

This was converted to the oxalate salt by the method of Example 16.

Example 600. 7-Nitro-1H-indole-2-carboxylic acid {1-[(R)-2-hydroxy-2-(6-methoxyquinolin-4-yl)-ethyl]-piperidin-4-yl}-amide mesylate



7-Nitro-1H-indole-2-carboxylic acid (34 mg) in dimethylformamide (0.4ml) was treated with was O-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (63mg), diisopropylethylamine (0.03ml, and amine (1d) and the mixture was agitated at room temperature for 4 hours. It was partitioned between dichloromethane and sodium bicarbonate solution and the organic layer was evaporated and purified on silica gel using a methanol-ethyl acetate gradient to give the free base of the title compound (29mg) as a foam.

MS (+ve ion electrospray) m/z 490 (MH⁺)

¹H NMR (CDCl₃): δ: 1.70 (6H, m), 2.10-2.65 (4H, m), 2.90 (2H, m), 3.35 (1H, br.d), 3.95 (3H, s), 5.50 (1H, m), 6.20 (1H, br.d), 7.00 (1H, s), 7.20 (1H, s), 7.25 (1H, m), 7.38 (1H, dd), 7.65 (1H, d), 7.95 (1H, d), 8.10 (1H, d), 8.30 (1H, d), 8.80 (1H, d).


This was converted to the mesylate salt by treatment with methane sulfonic acid in ether.

The following compounds were prepared by an analogous method to Example 600

Example	salt G oxalate S mesylate B dihydrochloride	X	R
601	S	CH	benzo[1,2,5]thiadiazol-5-yl
602	S	CH	4,6-difluoro-1H-indol-2-yl
603	G	N ^a	benzofuran-2-yl
604	S	CH	benzofuran-2-yl
605	S	CH	benzo[1,2,3]thiadiazol-5-yl
606	B	CH	1H-pyrrolo[2,3-b]pyridin-2-yl
607	S	CH	1H-indol-2-yl
608	S	CH	quinolin-3-yl
609	S	CH	benzothiazol-6-yl
610	S	CH	1H-indol-6-yl
611	-	CH	5-trifluoromethyl-thieno[3,2-b]pyridin-6-yl
612	-	CH	benzothiophen-2-yl
613	-	CH	8-hydroxyquinolin-2-yl
614	-	CH	thieno[3,2-b]thiophen-2-yl
615	-	CH	2-(1-phenyl-methanoyl)-1,2,3,4-tetrahydro-isoquinolin-3-yl

616	CH	4-dimethylsulfamoyl-1-methoxy-naphthalen-2-yl
^a amine (18f) used in place of amine (1d)		

Example 620. 4-[(5-Hydroxy-quinoxalin-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (5,8-difluoro-6-methoxy-quinolin-4-yl)-amide oxalate



5

(a) 1,5-Difluoro-4-methoxy-phenylamine

1,2,4-Trifluoro-5-nitrobenzene (10g, 56.5mmol) was dissolved in methanol, cooled in ice and treated with 25% sodium methoxide in methanol. After being stirred at room temperature for 6 hours the mixture was diluted with water and extracted with ethyl acetate to give 1,4-difluoro-2-methoxy-5-nitrobenzene (10.1g). This was dissolved in ethanol (400ml) and hydrogenated over 10% palladium on carbon to give the title compound (7.8g).

(b) 1,1,1-Trifluoro-methanesulfonic acid 5,8-difluoro-6-methoxy-quinolin-4-yl ester
5,8-Difluoro-6-methoxyquinolin-4-ol was prepared from the amine (620a) (7.8g) by the method of Example (26a) (1.41g) and was converted to the title compound by the method of Example (26b). Purification on silica gel (dichloromethane) afforded a yellow solid (0.76g).

(c) 4-Amino-piperidine-1-carboxylic acid (5,8-difluoro-6-methoxy-quinolin-4-yl)-amide
This was prepared (43%) as a yellow solid from the triflate (620b) by the method of Example (150a-d).

(d) Title compound


This was prepared from amine (620c) (0.11g) and 5-hydroxy-quinoxalin-2-carboxaldehyde [prepared from 5-hydroxy-2-methylquinoxaline (Y. Abe et al, *J. Med. Chem.* 41, 4062 (1998)) by oxidation with selenium dioxide in ethyl acetate (see Example 18a)] (0.057g) by the method of Example (150g). Purification on silica gel (5-10% methanol/dichloromethane) afforded the free base of the title compound (0.059g).

¹H NMR (CDCl₃) δ: 1.54 (m), 1.76 (broad s), 2.08 (m), 2.90 (m), 3.12 (m), 4.02 (s), 4.10 (m), 4.24 (s), 7.25 (m), 7.63 (m), 8.45 (d), 8.57 (broad d), 8.67 (d), 8.77 (s).

MS (+ve ion electrospray)m/z 495 (MH⁺).

This was converted to the oxalate salt by the method of Example 16.

Example 621. 4-[(8-Hydroxy-quinoxalin-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (5,8-difluoro-6-methoxy-quinolin-4-yl)-amide oxalate




This was prepared from amine (620d) (0.05g) and 8-hydroxy-quinoxalin-2-carboxaldehyde [prepared from 8-hydroxy-2-methylquinoxaline (Y. Abe et al, *J. Med. Chem.* 41, 4062 (1998)) by oxidation with selenium dioxide in ethyl acetate (see Example 18a)] (0.025g) by the method of Example (150g). Purification on silica gel (5-10% methanol/dichloromethane) afforded the title compound (0.027g)

¹H NMR (CDCl₃) δ: 1.51(m), 2.08(m), 2.89(m), 3.11(m), 4.01(s), 4.11(m), 4.25(s), 7.26(m), 7.66(m), 8.44(d), 8.56(broad d), 8.67(d), 8.96(s).

MS (+ve ion electrospray) m/z 495 (MH⁺).

This was converted to the oxalate salt by the method of Example 16.

Example 622. (R)-2-{4-[(8-Hydroxy-1-oxo-1,2-dihydro-isoquinolin-3-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol trihydrochloride



(a) Ethyl 2-methoxymethoxy-6-methylbenzoic acid

A solution of ethyl 2-hydroxy-6-methylbenzoic acid (4.56g, 25.3 mmol) and diisopropylethylamine (13.2ml, 76 mmol) in dry dichloromethane (30ml) was cooled in an ice-bath. Chloromethyl methyl ether (3.83ml, 50.6 mmol) was added slowly and the mixture was allowed stand at 0°C, warming slowly to room temperature. After 36 h a further portion of chloromethyl methyl ether (1.9 ml) was added and the mixture was left at room temperature overnight. The mixture was then washed with 10% citric acid, water and brine, dried and evaporated to give the title compound (6.34g, 100%).

MS (+ve ion electrospray) m/z 225 (MH⁺).

(b) 8-Methoxymethoxy-1-oxo-1H-isochromene-3-carboxylic acid ethyl ester

n-Butyllithium (1.6M in hexanes, 16.0ml, 25.5 mmol) was added to a solution of diisopropylamine (3.64ml, 25.5 mmol) and N,N,N',N'-tetramethylethylenediamine (4.01ml, 25.5 mmol) in dry THF (36ml) at -78 °C. After 10 min a solution of the ester (622a) (5.10g, 22.8 mmol) in dry THF (18ml) was added dropwise, keeping internal

temp. < -60 °C. The deep red solution was stirred at -78 °C for 40 minutes, then diethyl oxalate (3.10ml, 22.8 mmol) in THF (18ml) was added over 5 minutes. The mixture was stirred at -78 °C for 6.5 hours, then treated with 10% citric acid. After warming to room temperature the phases were separated and the aqueous phase was extracted with ethyl acetate. The combined organics were washed with brine, dried and evaporated.
5 Chromatography on silica gel (20-40% ethyl acetate/ hexane) gave the title compound (2.05g, 32%).

MS (+ve ion electrospray) m/z 235 (loss of methoxymethyl from MH+).

(c) 8-Methoxymethoxy-1,2-dihydro-1-oxo-isoquinoline-3-carboxylic acid ethyl ester
10 The isochromene (622b) (2.04g, 7.34 mmol) was heated under reflux with ammonium acetate (4.99g) in ethanol (200ml) for 24 hours. Solvent was evaporated and the residue was dissolved in ethyl acetate and water. The aqueous phase was extracted with ethyl acetate and combined organics were washed with water, dried and evaporated. Chromatography on silica gel (50-100% ethyl acetate/hexane) gave impure product and
15 recovered isochromene. The latter was treated again with ammonium acetate (1.3g) in refluxing ethanol (50 ml) for 48 hours, then worked up as before. The crude material was combined with the initial impure product for chromatography on silica gel (0-2% methanol/dichloromethane). Eluted material was rechromatographed (50-100% ethyl acetate/hexane) to give the title compound (0.87g, 42%).

20 MS (+ve ion electrospray) m/z 278 (MH+).

(d) 8-Hydroxy-3-hydroxymethyl-2H-isoquinolin-1-one

The ester (622c) (0.66g, 2.38 mmol) and sodium borohydride (0.14g, 3.6 mmol) were heated in refluxing t-butanol (3ml) while methanol (0.6ml) was added over 1 hour. Heating was continued for 2 hours, then the cooled mixture was partitioned between ethyl
25 acetate and water. The aqueous phase was re-extracted with ethyl acetate and the combined organics were washed with brine, dried and evaporated to give the title compound (0.51g, 91%).

MS (+ve ion electrospray) m/z 236 (MH+).

(e) 8-Methoxymethoxy-1,2-dihydro-1-oxo-isoquinoline-3-carboxaldehyde
30 The alcohol (622d, 0.51g, 2.17 mol) was stirred with manganese (IV) oxide (3.12g) in 1:1 dichloromethane/THF (40 ml) at room temperature for 5 hours. The mixture was filtered and evaporated to give the aldehyde (0.32g, 63%).

MS (-ve ion electrospray) m/z 232 (M-H).

(f) (R)-2-{4-[(8-Methoxymethoxy-1-oxo-1,2-dihydro-isoquinolin-3-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol
35


The aldehyde (622e) (0.080g, 0.34 mol) and 4-amino-1-[2-(R)-hydroxy-2-(6-methoxyquinolin-4-yl)]ethylpiperidine (1d) (0.105g, 0.35 mmol) were stirred with 3A

molecular sieves in dry dichloromethane (2ml) and methanol (2ml) overnight. Sodium borohydride (0.02g) was added and the mixture was stirred at room temperature overnight. After two further additions of sodium borohydride (0.02g each) the mixture was stirred overnight again. Water and dichloromethane were added, phases were separated and the aqueous phase was extracted with dichloromethane. Combined organics were washed with water, dried and evaporated. Chromatography on silica gel (2-10% methanol/dichloromethane) gave the title compound (0.064g, 35%).
 MS (+ve ion electrospray) m/z 519 (MH⁺).

(g) Title compound

The methoxymethyl compound (622f) (0.097g, 0.19 mmol) was partially dissolved in 5M hydrochloric acid (5ml) and 1,4-dioxane (5ml) and stirred at room temperature for 4 hours. Evaporation to dryness gave the title compound (0.105g, 95%).
 δ H (d₆-DMSO, 250MHz), 2.24 (2H, m), 2.39 (2H, m), 3.1-3.5 (5H, m), 3.83 (1H, m), 4.11 (4H, s), 4.20 (2H, s), 6.38 (1H, d), 6.86 (1H, d), 6.94 (1H, s), 7.09 (1H, d), 7.62 (1H, t), 7.76 (1H, dd), 7.83 (1H, s), 8.05 (1H, d), 8.32 (1H, d), 9.08 (1H, d)
 MS (+ve ion electrospray) m/z: 475 (MH⁺).

Example 623. (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(thiazolo[5,4-b]pyridin-6-ylmethyl)-amino]-piperidin-1-yl}-ethanol dioxalate



(a) 5-Amino-6-thioxo-1,6-dihydro-pyridine-3-carboxylic acid methyl ester

A mixture of sodium sulfide nonahydrate (2.17g) and sulfur (0.29g) was heated in boiling water (20ml) until the solution was homogeneous and added to a solution of 6-chloro-5-nitro-nicotinic acid methyl ester [prepared as described by A.H. Berrie *et al.* *J. Chem. Soc.* 2590-2594 (1951)] (3.10g) in methanol (50ml). The mixture was boiled for 15 minutes and cooled. The resulting disulfide was collected and washed with water to give a yellow solid (2.46g). The solid (5g) in acetic acid (100ml) and 4M HCl in dioxane (50ml) was treated with zinc dust (12g) and the mixture was stirred at room temperature for 30 minutes, filtered and evaporated to dryness. Sodium acetate and sodium sulfate were added and the mixture was extracted with warm chloroform and chromatographed on silica gel, eluting with chloroform then methanol-chloroform to afford a yellow solid (2.3g).

MS (+ve ion electrospray) m/z 185 (MH⁺)

(b) Thiazolo[5,4-b]pyridine-6-carboxylic acid methyl ester

The amine (623a) (0.7g) was heated in formic acid (30ml) under reflux for 30 minutes and was evaporated and chromatographed on silica gel (chloroform) to give a solid (0.65g).

MS (+ve ion electrospray) m/z 195(MH⁺)

5 (c) Thiazolo[5,4-b]pyridin-6-yl-methanol

A solution of ester (623b) (200mg) in dry tetrahydrofuran (15ml) and dry ether (15ml); cooled to -45°C, was treated with a 1M solution of lithium aluminium hydride in ether (1.55 ml) and the mixture was heated under reflux for 18 hours. It was cooled and a solution of saturated sodium carbonate was added cautiously. Dichloromethane and anhydrous sodium sulfate were added and the mixture was stirred for 15 minutes and filtered. The filtrate was evaporated to afford a white solid (95mg).

MS (+ve ion electrospray) m/z 167(MH⁺)

(d) Thiazolo[5,4-b]pyridine-6-carboxaldehyde

The alcohol (623c) (65mg) in chloroform (10ml) was stirred with manganese dioxide (200mg) for 5 hours, filtered and evaporated and chromatographed on silica gel, eluting with dichloromethane then chloroform, to give a solid (65mg).

MS (+ve ion electrospray) m/z 165(MH⁺)

(e) Title compound


A solution of the amine (1d; 94% ee) (81mg) and carboxaldehyde (623d) (40mg) in dichloromethane (3ml) and methanol (3ml) was treated with 3A molecular sieves and the mixture was heated at 50°C for 4 hours. The mixture was cooled and treated with sodium borohydride (27mg) and stirred at room temperature for 18 hours. It was filtered, evaporated to dryness, diluted with water, extracted with chloroform and chromatographed on silica gel (methanol-dichloromethane) to afford the free base of the title compound as an oil (40mg).

δ H (CDCl₃): 1.60 (2H, m), 2.10 (2H, br. t), 2.15-2.70 (4H, m), 2.80 (2H, dd), 3.30 (1H, br. d), 3.90 (3H, s), 4.05 (2H, s), 5.45 (1H, dd), 7.17 (1H, d), 7.35 (1H, dd), 7.66 (1H, d), 8.04 (1H, d), 8.38 (1H, s), 8.65 (1H, s), 8.75 (1H, d), 9.12 (1H, s).

MS (+ve ion electrospray) m/z 450 (MH⁺).

30 The dioxalate salt was prepared by the same method as for Example 1.

Example 624. (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(1-carboxymethyl-1H-pyrrolo[2,3-b]pyridine-2-yl)methyl]-amino}-piperidin-1-yl}-ethanol trihydrochloride



(a) (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[(1-*tert*-butoxycarbonylmethyl-1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol

To a suspension of sodium hydride (60% in mineral oil, 0.02g, 0.5 mmol) in dry THF at 0 °C was added (R)-1-(6-methoxy-quinolin-4-yl)-2-{4-[(1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol (Example 17 free base) (0.20g, 0.46 mmol). After stirring for 0.5 hours at 0 °C, *tert*-butyl bromoacetate (0.081ml, 0.5 mmol) was added. The mixture was stirred at room temperature overnight, then allowed to stand for another 48 hours. Solvent was evaporated and the residue was partitioned between dichloromethane/methanol and water. The organic phase was washed with water, dried and evaporated. Chromatography on silica gel (2-10% methanol/dichloromethane) gave the *tert*-butyl ester (0.053g, 21%) as the first-eluted product. MS (+ve ion electrospray) m/z: 546 (MH⁺).


(b) Title compound

The *tert*-butyl ester (624a, 0.053g) was dissolved in aqueous hydrochloric acid (2.5M) and the solution was allowed to stand at room temperature for 11 hours. It was evaporated to dryness to give the title compound (0.058g).

¹H NMR (CD₃OD) δ: 2.41 (2H, m), 2.60 (2H, m), 3.4-3.65 (4H, m), 3.85 (1H, m), 4.04 (1H, m), 4.19 (4H, s), 4.73 (2H, s), 5.44 (2H, s), 6.45 (1H, d), 7.27 (1H, s), 7.61 (1H, dd), 7.86 (2H, m), 8.23 (1H, d), 8.35 (1H, d), 8.52 (1H, d), 8.66 (1H, d), 9.07 (1H, d).

MS (+ve ion electrospray) m/z 490 (MH⁺).

Example 625. (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[carboxymethyl-(1-carboxymethyl-1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol dihydrochloride



(a) (R)-1-(6-Methoxy-quinolin-4-yl)-2-{4-[*tert*-butoxycarbonylmethyl-(1-*tert*-butoxycarbonylmethyl-1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol

This compound was prepared as for Example 624a, the diester being the second eluted product from chromatography (0.063g, 21%).

MS (+ve ion electrospray) m/z 660 (MH⁺).

(b) Title compound

The di-*tert*-butyl ester (624a, 0.063g) was dissolved in aqueous hydrochloric acid (2.5M) and the solution was allowed to stand at room temperature overnight. It was evaporated to dryness to give the title compound (0.058g).

¹H NMR (CD₃OD) δ: 2.3-2.55 (4H, m), 3.35 -3.65 (4H, m), 3.81 (1H, m), 4.00 (1H, m),
5 4.12 (2H,s), 4.18 (4H, s), 4.71 (2H, s), 5.75(2H, s), 6.45 (1H, d), 7.23 (1H, s), 7.69 (1H, t), 7.84 (1H, s), 7.86 (1H, d), 8.22 (1H, d), 8.33 (1H, d), 8.59 (1H, d), 8.78 (1H, d), 9.06 (1H, d).

MS (+ve ion electrospray) m/z 548 (MH⁺).


10

Biological Activity

The MIC (µg/ml) of test compounds against various organisms was determined:
S. aureus Oxford, S. aureus WCUH29, S. pneumoniae 1629, S. pneumoniae N1387,
15 S. pneumoniae ERY 2, E. faecalis 1, H. influenzae Q1, M. catarrhalis 1502.
Examples 1-8, 11-13, 16-25, 50-63, 67, 71, 73, 74, 91-107, 150, 300-306, 308, 309, 400-402, 405, 407-411, 601, 602, 604, 611-614, 622 have an MIC of less than or equal to 0.125µg/ml; 10, 14,15, 64-66, 68-70, 72, 75-85, 87, 108-113, 115-123, 150, 151, 170, 171, 307, 310, 312, 403, 404, 406, 412-414, 603, 605, 606-610, 623 have an MIC of less
20 than or equal to 2µg/ml; 9, 11, 86, 88-90, 114, 620, 624, 625 have an MIC less than or equal to 32µg/ml against one or more of the above range of gram positive and gram negative bacteria.

Claims

1. a compound of formula (I) or a pharmaceutically acceptable derivative thereof:



wherein:

one of Z^1, Z^2, Z^3, Z^4 and Z^5 is N, one is CR^{1a} and the remainder are CH, or one or two of Z^1, Z^2, Z^3, Z^4 and Z^5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6}) alkoxy optionally substituted by (C_{1-6}) alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6}) alkylthio, heterocyclythio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6}) alkylsulphonyloxy; (C_{1-6}) alkoxy-substituted (C_{1-6}) alkyl; halogen; (C_{1-6}) alkyl; (C_{1-6}) alkylthio; trifluoromethyl; trifluoromethoxy; nitro; azido; acyl; acyloxy; acylthio; (C_{1-6}) alkylsulphonyl; (C_{1-6}) alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6}) alkyl, acyl or (C_{1-6}) alkylsulphonyl groups;

provided that when Z^1, Z^2, Z^3, Z^4 and Z^5 are CR^{1a} or CH, then R^1 is not hydrogen;

R^2 is hydrogen, or (C_{1-4}) alkyl or (C_{2-4}) alkenyl optionally substituted with 1 to 3 groups selected from:

amino optionally substituted by one or two (C_{1-4}) alkyl groups; carboxy; (C_{1-4}) alkoxycarbonyl; (C_{1-4}) alkylcarbonyl; (C_{2-4}) alkenyloxycarbonyl; (C_{2-4}) alkenylcarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C_{1-4}) alkyl, hydroxy (C_{1-4}) alkyl, aminocarbonyl (C_{1-4}) alkyl, (C_{2-4}) alkenyl, (C_{1-4}) alkylsulphonyl, trifluoromethylsulphonyl, (C_{2-4}) alkenylsulphonyl, (C_{1-4}) alkoxycarbonyl, (C_{1-4}) alkylcarbonyl, (C_{2-4}) alkenyloxycarbonyl or (C_{2-4}) alkenylcarbonyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R^{10} ; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R^{10} ; 5-oxo-1,2,4-oxadiazol-

3-yl; halogen; (C₁₋₄)alkylthio; trifluoromethyl; hydroxy optionally substituted by (C₁₋₄)alkyl, (C₂₋₄)alkenyl, (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋₄)alkenyloxycarbonyl, (C₂₋₄)alkenylcarbonyl; oxo; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or (C₁₋₄)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl;

R³ is hydrogen; or

R³ is in the 2-, 3- or 4-position and is:

carboxy; (C₁₋₆)alkoxycarbonyl; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, trifluoromethylsulphonyl, (C₂₋₆)alkenylsulphonyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; cyano; tetrazolyl; 2-oxo-oxazolidinyl optionally substituted by R¹⁰; 3-hydroxy-3-cyclobutene-1,2-dione-4-yl; 2,4-thiazolidinedione-5-yl; tetrazol-5-ylaminocarbonyl; 1,2,4-triazol-5-yl optionally substituted by R¹⁰; or 5-oxo-1,2,4-oxadiazol-3-yl; or (C₁₋₄)alkyl or ethenyl optionally substituted with any of the substituents listed above for R³ and/or 0 to 2 groups R¹² independently selected from:


halogen; (C₁₋₆)alkylthio; trifluoromethyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; or when R³ is in the 3-position, hydroxy optionally substituted as described above;

in addition when R^3 is disubstituted with a hydroxy or amino containing substituent and carboxy containing substituent these may together form a cyclic ester or amide linkage, respectively;

R^4 is a group $-U-R^5$ where

5 U is selected from CO, SO₂ and CH₂ and

R^5 is an optionally substituted bicyclic carbocyclic or heterocyclic ring system (A):



containing up to four heteroatoms in each ring in which

ring (a) is aromatic or non aromatic;

10 X^1 is C when part of an aromatic ring or CR¹⁴ when part of a non aromatic ring;

X^2 is N, NR¹³, O, S(O)_x, CO or CR¹⁴ when part of an aromatic or non-aromatic ring or may in addition be CR¹⁴R¹⁵ when part of a non aromatic ring;

X^4 is N, NR¹³, O, S(O)_x, CO or CR¹⁴;

X^3 and X^5 are independently N or C;

15 Y^1 is a 1 to 3 atom linker group each atom of which is independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴ when part of an aromatic or non-aromatic ring or may additionally be CR¹⁴R¹⁵ when part of a non aromatic ring,

Y^2 is a 2 or 3 atom linker group completing an aromatic ring, each atom of Y^2 being independently selected from N, NR¹³, O, S(O)_x, CO and CR¹⁴;

20 each of R¹⁴ and R¹⁵ is independently selected from: H; (C₁₋₄)alkylthio; halo; carboxy(C₁₋₄)alkyl; halo(C₁₋₄)alkoxy; halo(C₁₋₄)alkyl; (C₁₋₄)alkyl; (C₂₋₄)alkenyl; (C₁₋₄)alkoxycarbonyl; formyl; (C₁₋₄)alkylcarbonyl; (C₂₋₄)alkenyloxycarbonyl; (C₂₋₄)alkenylcarbonyl; (C₁₋₄)alkylcarbonyloxy; (C₁₋₄)alkoxycarbonyl(C₁₋₄)alkyl; hydroxy; hydroxy(C₁₋₄)alkyl; mercapto(C₁₋₄)alkyl; (C₁₋₄)alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₄)alkylsulphonyl; (C₂₋₄)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C₁₋₄)alkyl or (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; aryl(C₁₋₄)alkoxy or

R¹⁴ and R¹⁵ may together represent oxo;

30 each R¹³ is independently H; trifluoromethyl; (C₁₋₄)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, carboxy, halo or trifluoromethyl; (C₂₋₄)alkenyl; aryl; aryl(C₁₋₄)alkyl; arylcarbonyl; heteroarylcarbonyl; (C₁₋₄)alkoxycarbonyl; (C₁₋₄)alkylcarbonyl; formyl; (C₁₋₆)alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₄)alkoxycarbonyl, (C₁₋₄)alkylcarbonyl, (C₂₋

4) alkenyloxycarbonyl, (C₂₋₄) alkenylcarbonyl, (C₁₋₄) alkyl or (C₂₋₄) alkenyl and optionally further substituted by (C₁₋₄) alkyl or (C₂₋₄) alkenyl;

n is 0 or 1;

5

each x is independently 0, 1 or 2

A is NR¹¹, O or CR⁶R⁷ and B is NR¹¹, O, SO₂ or CR⁸R⁹ and wherein:
each of R⁶, R⁷, R⁸ and R⁹ is independently selected from: hydrogen; (C₁₋₆) alkoxy; (C₁₋₆) alkylthio; halo; trifluoromethyl; azido; (C₁₋₆) alkyl; (C₂₋₆) alkenyl; (C₁₋₆) alkoxy carbonyl; (C₁₋₆) alkyl carbonyl; (C₂₋₆) alkenyloxycarbonyl; (C₂₋₆) alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for corresponding substituents in R³; (C₁₋₆) alkylsulphonyl; (C₂₋₆) alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆) alkyl or (C₂₋₆) alkenyl;
or when n=1 R⁶ and R⁸ together represent a bond and R⁷ and R⁹ are as above defined;
or R⁶ and R⁷ or R⁸ and R⁹ together represent oxo;

10

15

provided that:

20

when A is NR¹¹, B is not NR¹¹ or O;

when A is CO, B is not CO, O or SO₂;

when n is 0 and A is NR¹¹, CR⁸R⁹ can only be CO;

when A is CR⁶R⁷ and B is SO₂, n is 0;

when n is 0, B is not NR¹¹ or O or R⁸ and R⁹ are not optionally substituted hydroxy or amino;

25

when A is O, B is not NR¹¹, O, SO₂ or CO and n=1; and

when A-B is CR⁷=CR⁹, n is 1

R¹⁰ is selected from (C₁₋₄) alkyl; (C₂₋₄) alkenyl and aryl any of which may be optionally substituted by a group R¹² as defined above; carboxy; aminocarbonyl wherein the amino group is optionally substituted by hydroxy, (C₁₋₆) alkyl, (C₂₋₆) alkenyl, (C₁₋₆) alkylsulphonyl, trifluoromethylsulphonyl, (C₂₋₆) alkenylsulphonyl, (C₁₋₆) alkoxy carbonyl, (C₁₋₆) alkyl carbonyl, (C₂₋₆) alkenyloxycarbonyl or (C₂₋₆) alkenylcarbonyl and optionally further substituted by (C₁₋₆) alkyl or (C₂₋₆) alkenyl;
(C₁₋₆) alkylsulphonyl; trifluoromethylsulphonyl; (C₂₋₆) alkenylsulphonyl; (C₁₋₆) alkoxy carbonyl; (C₁₋₆) alkyl carbonyl; (C₂₋₆) alkenyloxycarbonyl; and (C₂₋₆) alkenylcarbonyl; and

30

35

R¹¹ is hydrogen; trifluoromethyl, (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₂₋₆)alkenyl and optionally further substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl;

or where one of R³ and R⁶, R⁷, R⁸ or R⁹ contains a carboxy group and the other contains a hydroxy or amino group they may together form a cyclic ester or amide linkage.

10

2. A compound according to claim 1 wherein Z⁵ is CH or N, Z³ is CH or CF and Z¹, Z² and Z⁴ are each CH, or Z¹ is N, Z³ is CH or CF and Z², Z⁴ and Z⁵ are each CH.

15

3. A compound according to any preceding claim wherein R¹ is methoxy, amino(C₃₋₅)alkyloxy or guanidino(C₃₋₅)alkyloxy.

20

4. A compound according to any preceding claim wherein R² is hydrogen, carboxymethyl, hydroxyethyl, aminocarbonylmethyl, ethoxycarbonylmethyl, ethoxycarbonylallyl or carboxyallyl.

5. A compound according to any preceding claim wherein R³ is hydrogen; optionally substituted hydroxy, (C₁₋₄) alkyl; ethenyl; optionally substituted 1-hydroxy-(C₁₋₄) alkyl; optionally substituted aminocarbonyl; carboxy(C₁₋₄)alkyl; optionally substituted aminocarbonyl(C₁₋₄)alkyl; cyano(C₁₋₄)alkyl; optionally substituted 2-oxo-oxazolidinyl or optionally substituted 2-oxo-oxazolidinyl(C₁₋₄alkyl) in the 3- or 4-position.

25

6. A compound according to any preceding claim wherein n is 0, A-B is CHOH-CH₂, NR¹¹-CH₂ or NR¹¹-CO and R¹¹ is hydrogen or (C₁₋₄)alkyl.

30

7. A compound according to any preceding claim wherein U is CH₂ and R⁵ is an aromatic heterocyclic ring (A) having 1-4 heteroatoms of which one is N or NR¹³, R¹³ is H if in ring (a) or in addition (C₁₋₄)alkyl, R¹⁴ and R¹⁵ are independently selected from hydrogen, halo, hydroxy, (C₁₋₄)alkyl, (C₁₋₄)alkoxy, trifluoromethoxy, nitro, cyano, aryl(C₁₋₄)alkoxy and (C₁₋₄)alkylsulphonyl.

35

8. A compound according to any of claims 1 to 6 wherein R⁵ is 4,6-difluoro-indol-2-yl, 1H-pyrrolo[2,3-b]-pyridin-2-yl, 1H-pyrrolo[3,2-b]-pyridin-2-yl, 8-hydroxy-quinolin-

2-yl, quinoxalin-2-yl, benzimidazol-2-yl, benzo[1,2,3]-thiadiazol-5-yl, benzothiophen-2-yl, 4,6-difluoro-1H-benzimidazol-2-yl, benzothiazole-5-yl or 3-(R)-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl.

- 5 9. A compound according to claim 1 selected from:
- (R)-2-{4-[(4-fluoro-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxyquinolin-4-yl)-ethanol;
- (R)-1-(6-methoxy-quinolin-4-yl)-2-{4-[(1H-pyrrolo[2,3-b]pyridine-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol;
- 10 2-({1-[(R)-2-hydroxy-2-(6-methoxy-quinolin-4-yl)-ethyl]-piperidin-4-ylamino}-methyl)-quinolin-8-ol;
- (R)-2-{4-[(benzo[1,2,3]thiadiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol;
- (R)-1-(6-methoxy-quinolin-4-yl)-2-{4-[(quinoxalin-2-ylmethyl)-amino]-piperidin-1-yl}-ethanol;
- 15 2-({1-[(R)-2-hydroxy-2-(6-methoxy-[1,5]naphthyridin-4-yl)-ethyl]-piperidin-4-ylamino}-methyl)-quinolin-8-ol;
- 4-[(4,7-difluoro-1H-indol-2-ylmethyl)-amino]-piperidine-1-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)-amide;
- 20 (R)-2-{4-[(R)-1-(2,3-Dihydro-[1,4]dioxino[2,3-b]pyridin-3-yl)methyl]-amino}-piperidin-1-yl}-1-(8-fluoro-6-methoxy-quinolin-4-yl)-ethanol;
- (R)-2-{4-[(Benzothiazol-5-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy-quinolin-4-yl)-ethanol;
- (R)-2-{4-[(4,6-Difluoro-1H-benzimidazol-2-ylmethyl)-amino]-piperidin-1-yl}-1-(6-methoxy[1,5]naphthyridin-4-yl)-ethanol;
- 25 and pharmaceutically acceptable derivatives thereof.


10. A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound according to claim 1.
- 30

11. The use of a compound according to claim 1, in the manufacture of a medicament for use in the treatment of bacterial infections in mammals.


12. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier.

- 35 13. A process for preparing compounds according to claim 1, which process comprises:

reacting a compound of formula (IV) with a compound of formula (V):




(IV)



(V)

- 5 wherein n is as defined in formula (I); $Z^1, Z^2, Z^3, Z^4, Z^5, R^1$ and R^3 are $Z^1, Z^2, Z^3, Z^4, Z^5, R^1$ and R^3 as defined in formula (I) or groups convertible thereto;
 Q^1 is NR^2R^4 or a group convertible thereto wherein R^2 and R^4 are R^2 and R^4 as defined in formula (I) or groups convertible thereto and Q^2 is H or R^3 or Q^1 and Q^2 together form an optionally protected oxo group;
- 10 and X and Y may be the following combinations:
- (i) X is A'-COW, Y is H and n is 0;
 - (ii) X is $CR^6=CR^8R^9$, Y is H and n is 0;
 - (iii) X is oxirane, Y is H and n is 0;
 - (iv) X is $N=C=O$ and Y is H and n is 0;
 - 15 (v) one of X and Y is CO_2R^Y and the other is $CH_2CO_2R^X$;
 - (vi) X is CHR^6R^7 and Y is $C(=O)R^9$;
 - (vii) X is $CR^7=PR^2Z_3$ and Y is $C(=O)R^9$ and $n=1$;
 - (viii) X is $C(=O)R^7$ and Y is $CR^9=PR^2Z_3$ and $n=1$;
 - (ix) Y is COW and X is $NHR^{11'}$, NCO or $NR^{11'}COW$ and $n=0$ or 1 or when $n=1$ X
 - 20 is COW and Y is $NHR^{11'}$, NCO or $NR^{11'}COW$;
 - (x) X is $C(=O)R^6$ and Y is $NHR^{11'}$ or X is $NHR^{11'}$ and Y is $C(=O)R^8$ and $n=1$;
 - (xi) X is $NHR^{11'}$ and Y is CR^8R^9W and $n=1$;
 - (xii) X is CR^6R^7W and Y is $NHR^{11'}$ or OH and $n=1$;
 - (xiii) X is $CR^6R^7SO_2W$ and Y is H and $n=0$;
 - 25 (xiv) X is W or OH and Y is CH_2OH and $n=1$;
 - (xv) X is $NHR^{11'}$ and Y is SO_2W or X is $NR^{11'}SO_2W$ and Y is H, and $n=0$;
 - (xvi) X is $NR^{11'}COCH_2W$ or $NR^{11'}SO_2CH_2W$ and Y is H and $n=0$;
 - (xvii) X is W and Y is $CONHR^{11'}$;
- 30 in which W is a leaving group, e.g. halo or imidazolyl; R^X and R^Y are (C_{1-6}) alkyl; R^Z is aryl or (C_{1-6}) alkyl; A' and $NR^{11'}$ are A and NR^{11} as defined in formula (I), or groups convertible thereto; and oxirane is:



- wherein R^6 , R^8 and R^9 are as defined in formula (I);
 and thereafter optionally or as necessary converting Q^1 and Q^2 to $NR^{2'}R^{4'}$; converting A' ,
 Z^1 , Z^2 , Z^3 , Z^4 , Z^5 , R^1 , R^2 , R^3 , R^4 and $NR^{11'}$ to A , Z^1 , Z^2 , Z^3 , Z^4 , Z^5 , R^1 , R^2 , R^3 ,
 5 R^4 and $NR^{11'}$; converting A-B to other A-B, interconverting R^1 , R^2 , R^3 and/or R^4 ,
 and/or forming a pharmaceutically acceptable derivative thereof.

INTERNATIONAL SEARCH REPORT

Inter- national Application No
PCT/EP 01/08604

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/14 A61K31/47 A61K31/445 A61K31/4725 A61P31/04
C07D401/12 //(C07D401/14, 215:00, 211:00, 209:00), (C07D401/14,
307:00, 215:00, 211:00), (C07D401/14, 333:00, 215:00, 211:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 07432 A (DAVIES DAVID THOMAS ; MARKWELL ROGER EDWARD (GB); LIGHTFOOT ANDREW) 1 February 2001 (2001-02-01) cited in the application * overlap of chemical formula * the whole document	1-13
P, Y	WO 01 07433 A (MARKWELL ROGER EDWARD ; PEARSON NEIL DAVID (GB); SMITHKLINE BEECHAM) 1 February 2001 (2001-02-01) cited in the application * see claims 1-13, definition of R5 * the whole document --- -/-	1-13

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

19 December 2001

Date of mailing of the international search report

14/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/08604

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 (C07D401/14, 235:00, 215:00, 211:00), (C07D401/14, 311:00, 215:00, 211:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 00 78748 A (DAVIES DAVID THOMAS ; MARKWELL ROGER EDWARD (GB); PEARSON NEIL DAVI) 28 December 2000 (2000-12-28) cited in the application * see claims 1-12, definition of R5 * the whole document	1-13
P, Y	WO 00 43383 A (DAVIES DAVID THOMAS ; HENRY CAROLINE JOAN (GB); PEARSON NEIL DAVID) 27 July 2000 (2000-07-27) cited in the application * see claims 1-12, definition of R5 * the whole document	1-13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

19 December 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

Inter Application No
PC1/EP 01/08604

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 02438 A (COCKERILL GEORGE STUART ;GUNTRIP STEPHEN BARRY (GB); GLAXO GROUP L) 22 January 1998 (1998-01-22) * overlap of chemical formula * the whole document	1-13
Y	WO 00 21948 A (HATTON IAN KEITH ;PEARSON NEIL DAVID (GB); SMITHKLINE BEECHAM PLC) 20 April 2000 (2000-04-20) cited in the application * see claims 1-12, definition of R5 * the whole document	1-13
Y	WO 00 21952 A (DAVIES DAVID THOMAS ;MARKWELL ROGER EDWARD (GB); PEARSON NEIL DAVI) 20 April 2000 (2000-04-20) cited in the application * see claims 1-12, definition of R5 * the whole document	1-13
Y	WO 99 37635 A (COATES WILLIAM JOHN ;MASTERS PHILIP JOHN (GB); WARRACK JULIE DOROT) 29 July 1999 (1999-07-29) cited in the application * see claims 1-16, definition of R5 * the whole document.	1-13
Y	WO 97 28167 A (ORTHO PHARMA CORP) 7 August 1997 (1997-08-07) * see pages 1 - 3 * the whole document	1-13
Y	WO 95 09853 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 (1995-04-13) * see page 5, lines 5-35 * the whole document	1-13
Y	EP 0 374 095 A (CIBA GEIGY AG) 20 June 1990 (1990-06-20) * see p.3., line 17 -47 * the whole document	1-13

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08604

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0107432	A	01-02-2001	AU 5986200 A WO 0107432 A2	13-02-2001 01-02-2001
WO 0107433	A	01-02-2001	AU 6825300 A WO 0107433 A2	13-02-2001 01-02-2001
WO 0078748	A	28-12-2000	AU 5681800 A WO 0078748 A1	09-01-2001 28-12-2000
WO 0043383	A	27-07-2000	AU 2437900 A WO 0043383 A1 EP 1144404 A1	07-08-2000 27-07-2000 17-10-2001
WO 9802438	A	22-01-1998	AU 3443997 A BR 9710359 A CA 2260061 A1 CN 1230187 A CZ 9900089 A3 WO 9802438 A1 EP 0912570 A1 HR 970371 A1 JP 2000514445 T NO 990124 A PL 331221 A1 TR 9900049 T2 US 6174889 B1 ZA 9706146 A	09-02-1998 17-08-1999 22-01-1998 29-09-1999 16-06-1999 22-01-1998 06-05-1999 31-08-1998 31-10-2000 11-03-1999 05-07-1999 21-04-1999 16-01-2001 11-01-1999
WO 0021948	A	20-04-2000	AU 6114699 A EP 1127057 A1 WO 0021948 A1	01-05-2000 29-08-2001 20-04-2000
WO 0021952	A	20-04-2000	AU 6339599 A WO 0021952 A1 EP 1121355 A1	01-05-2000 20-04-2000 08-08-2001
WO 9937635	A	29-07-1999	AU 2717899 A WO 9937635 A1 EP 1051413 A1	09-08-1999 29-07-1999 15-11-2000
WO 9728167	A	07-08-1997	US 5707990 A AU 1684397 A WO 9728167 A1 ZA 9700738 A	13-01-1998 22-08-1997 07-08-1997 29-07-1998
WO 9509853	A	13-04-1995	AT 208772 T AU 691834 B2 AU 7697794 A CA 2148928 A1 CN 1115982 A ,B CZ 9501722 A3 WO 9509853 A1 EP 0672041 A1 FI 952607 A HU 72609 A2 IL 111077 A JP 2983636 B2 JP 8504215 T	15-11-2001 28-05-1998 01-05-1995 13-04-1995 31-01-1996 13-03-1996 13-04-1995 20-09-1995 29-05-1995 28-05-1996 28-10-1999 29-11-1999 07-05-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08604

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9509853	A	NO 952132 A	30-05-1995
		NZ 273617 A	26-11-1996
		PL 309225 A1	02-10-1995
		RU 2135491 C1	27-08-1999
		SG 45183 A1	16-01-1998
		TW 378208 B	01-01-2000
		US 5728708 A	17-03-1998
		ZA 9407657 A	03-04-1995
EP 0374095	A	20-06-1990	
		AU 4607689 A	14-06-1990
		CA 2004986 A1	12-06-1990
		DD 290186 A5	23-05-1991
		DK 623689 A	13-06-1990
		EP 0374095 A2	20-06-1990
		HU 53078 A2	28-09-1990
		JP 2212471 A	23-08-1990
		PT 92536 A	29-06-1990
		YU 233489 A1	28-02-1991
		ZA 8909436 A	29-08-1990